

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: October 12, 2005, 09:32:54 ; Search time 485 Seconds
(without alignments)
7799.412 Million cell updates/sec

Title: US-09-721-183-4
Perfect score: 639
Sequence: 1 ccgaacgaggttaggtcc.....cacgaatggacggaggat 639

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 4390206 seqs, 2959870667 residues

Total number of hits satisfying chosen parameters: 8780412

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : N_Geneseq_16Dec04.*
1: Geneseqn1980s.*
2: Geneseqn1990s.*
3: Geneseqn2000s.*
4: Geneseqn2001as.*
5: Geneseqn2001bs.*
6: Geneseqn2002as.*
7: Geneseqn2002bs.*
8: Geneseqn2003as.*
9: Geneseqn2003bs.*
10: Geneseqn2003cs.*
11: Geneseqn2003ds.*
12: Geneseqn2004as.*
13: Geneseqn2004bs.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	639	100.0	639	5	AAD06846 Human bre
2	637.4	99.7	1104	8	ABZ71575 Breast sp
3	637.4	99.7	1104	12	ADP85817 Human bre
4	501.8	78.5	1011	4	AAK89498 Human dig
5	498.2	78.0	611	4	AAK87973 Human dig
6	350.4	54.8	2360	6	ABZ22025 Human NIP
7	306	47.9	307	8	ABZ71574 Breast sp
8	306	47.9	307	12	ADP85816 Human bre
9	99.8	15.6	766	10	ADC32261 Human nov
10	99.8	15.6	1192	10	ADC30390 Human nov
11	99.8	15.6	2112	10	ADB62991 Human cdn
12	75.8	11.9	503	11	ACN92793 Breast ca
13	45.2	7.1	202251	11	ACN44504 Mouse gen
14	42	6.6	53522	6	ADP30228 Human PKD
15	42	6.6	53526	2	AAT94101 Human PKD
16	42	6.6	53577	2	AAT18551 Human pol
17	42	6.6	53577	2	AAT94108 Human PKD
18	39.2	6.1	540	13	ACN47094 Corton pr
19	38.4	6.0	2000	8	ADA71938 Rice gene
20	37.8	5.9	79640	13	ABD33007 Mouse can

21	37.4	5.9	1000	3	AAA02484	Aaa02484 Human col
22	37.4	5.9	118584	10	ADC87623	Adc87623 Human GPC
23	37.4	5.9	349999	10	ADC87010	Adc87010 Human GPC
24	37.2	5.8	1038	2	AAQ51019	Aaq51019 BBV VCA-p
25	37.2	5.8	172281	12	ADN12161	Adn12161 Epslein-B
26	36.6	5.7	10732	3	AAA10594	Aaa10594 Gene enco
27	36.2	5.7	203132	13	ABD33364	Abd33364 Murine ca
28	35.6	5.6	2230	11	ADM02845	Adm02845 Human cdn
29	35.6	5.6	7444	8	ABT19632	Abt19632 Aspergill
30	35.6	5.6	7496	8	ABT17818	Abt17818 Aspergill
31	35.6	5.6	8456	13	ADR84410	Adr84410 Aspergill
32	35.2	5.5	134442	13	ABD32824	Abd32824 Mouse can
33	35	5.5	1527	5	AAS68546	Aas68546 DNA enco
34	35	5.5	1620	5	AAS68547	Aas68547 DNA enco
35	35	5.5	2178	5	AAS86106	Aas86106 DNA enco
36	35	5.5	26047	11	ACN44246	Acn44246 Human gen
37	34.8	5.4	500	6	ABN15750	Abn15750 Human gen
38	34.8	5.4	500	13	ACN78840	Acn78840 Human GDM
39	34.8	5.4	505	12	ACH73908	Ach73908 Human gen
40	34.8	5.4	1967	4	AAI13118	Aai13118 Probe #30
41	34.8	5.4	1967	4	ABA54817	Abas4817 Human foe
42	34.8	5.4	1967	4	AAI34469	Aai34469 Probe #31
43	34.8	5.4	1967	4	ABA44363	Abas44363 Human bre
44	34.8	5.4	1967	4	ABA24581	Abas24581 Probe #30
45	34.8	5.4	1967	4	AAK28545	Aak28545 Human bon

ALIGNMENTS

RESULT 1
AAD06846
ID AAD06846 standard; DNA; 639 BP.
XX
AC AAD06846;
XX
DT 06-AUG-2001 (first entry)
XX
DE Human breast cancer specific gene-4 (BCSG-4).
XX
KW Human; breast cancer specific gene-4; BCSG-4; cytostatic; vaccine;
KW breast cancer; therapeutic; gene therapy; ds.
XX
OS Homo sapiens.
XX
PN WO200137779-A2.
XX
PD 31-MAY-2001.
XX
PF 22-NOV-2000; 2000WO-US032056.
XX
PR 23-NOV-1999; 99US-0166973P.
XX
XX (DIAD-) DIADEXUS INC.
XX
PI Salceda S, Cafferkey R, Recipon H, Sun Y;
DR WPI; 2001-367602/38.
XX
PT Novel breast cancer specific gene for diagnosing, monitoring, staging,
PT imaging, preventing and treating cancers, particularly breast cancer.
XX
XX Claim 1; Page 51; 66pp; English.
XX
CC The invention relates human breast cancer specific genes (BCSG's) and
CC their corresponding proteins. BCSG is useful for diagnosing, staging,
CC monitoring, imaging, preventing and treating breast cancers. BCSG is also
CC useful for inducing an immune response against a target cell expressing
CC BCSG. The invention also provide methods for detecting genetic lesions or
CC mutations in BCSG, thereby determining if a human with the genetic lesion
CC is at risk for breast cancer or has breast cancer. BCSG antibodies
CC labelled with paramagnetic ions or radioisotopes is useful for imaging
CC breast cancers, while BCSG antibodies conjugated to a cytotoxic agent is

CC useful for treating breast cancer. BCSG is useful in the rational design
CC of new therapeutics for imaging and treating cancers. BCSG is also used
CC in gene therapy. The present DNA sequence is human breast cancer specific
CC gene-4 (BCSG-4) or Gene ID 173388
XX
SQ Sequence 639 BP; 146 A; 148 C; 168 G; 177 T; 0 U; 0 Other;

Query Match 100.0%; Score 639; DB 5; Length 639;
Best Local Similarity 100.0%; Pred. No. 7.4e-188; Length 639;
Matches 639; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CCAGAACCGAGTTTAGGTCAGGTTCTCGTTCTGGCAAAATCTTTCTCCTTACCTTCTTCC 60
Db | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
1 CCAGAACCGAGTTTAGGTCAGGTTCTCGTTCTGGCAAAATCTTTCTCCTTACCTTCTTCC 60
Qy 61 TCACCCCTCACCTATGCAATGTTTCCCTTAGCCACTCCCAAGCTCGGTGGAGGAAG 120
Db | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
61 TCACCCCTCACCTATGCAATGTTTCCCTTAGCCACTCCCAAGCTCGGTGGAGGAAG 120
Qy 121 GCAGGCTTAAGTACCGTCTTCCGACTTTGCTCAATGATAGCTGGGTGGTCTAGC 180
Db | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
121 GCAGGCTTAAGTACCGTCTTCCGACTTTGCTCAATGATAGCTGGGTGGTCTAGC 180
Qy 181 TGGTTCACGCACTTGTAAATGTGGACATCTCTCACCCCAACTTTGTAGTGGAGCAAC 240
Db | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
181 TGGTTCACGCACTTGTAAATGTGGACATCTCTCACCCCAACTTTGTAGTGGAGCAAC 240
Qy 241 TGCTACAGAGTAATATGATTAATCTTACATTCCTTCTGCTGCTCCCAACTTAA 300
Db | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
241 TGCTACAGAGTAATATGATTAATCTTACATTCCTTCTGCTGCTCCCAACTTAA 300
Qy 301 CAGCAGGTAACTCTCTTAGCAAGTGTGAAGTAAGAGAGCATCTGTATAGAGGCA 360
Db | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
301 CAGCAGGTAACTCTCTTAGCAAGTGTGAAGTAAGAGAGCATCTGTATAGAGGCA 360
Qy 361 AGAGATCTGAGTCTCTTTGAAGGCTATCTCTCTGCTGTATCTCAATTACTGTCTTCA 420
Db | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
361 AGAGATCTGAGTCTCTTTGAAGGCTATCTCTCTGCTGTATCTCAATTACTGTCTTCA 420
Qy 421 TTTCAAATATCTTACCTACTATTAATCAGTTCCTTGATCTTTTCTTCTTGGGGCTGCTT 480
Db | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
421 TTTCAAATATCTTACCTACTATTAATCAGTTCCTTGATCTTTTCTTCTTGGGGCTGCTT 480
Qy 481 AGGTCAGGGAGATTGCAGAGCACCAAGACTAGGAGCAGCCCTGAGACATGGGGAGTTG 540
Db | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
481 AGGTCAGGGAGATTGCAGAGCACCAAGACTAGGAGCAGCCCTGAGACATGGGGAGTTG 540
Qy 541 GAGCTGAAGGAGGAATGGCAGGATGAAGAAATTCCTTAGTGAGGACGTTGTGAGGGTGGCT 600
Db | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
541 GAGCTGAAGGAGGAATGGCAGGATGAAGAAATTCCTTAGTGAGGACGTTGTGAGGGTGGCT 600
Qy 601 GGGAGAGGGAGGGTGGTACGAATGGACGGAGGGAT 639
Db | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
601 GGGAGAGGGAGGGTGGTACGAATGGACGGAGGGAT 639

RESULT 2
ID ABZ71575 standard; cDNA; 1104 BP.
XX
AC ABZ71575;

XX 04-APR-2003 (first entry)
XX Breast specific nucleic acid # SEQ ID 35.
DE Human; breast specific nucleic acid; breast cancer; gene therapy;
XX cytosolic; ss.
XX Homo sapiens.
XX
PN WO20028837-A2.
XX

PD 07-NOV-2002.
XX
XX 29-OCT-2001; 2001WO-US051318.
XX
PR 27-OCT-2000; 2000US-0243805P.
XX
XX (DIAD-) DIADEXUS INC.
XX
XX Sun Y, Recipon H, Salceda S, Liu C, Turner LR,
XX WPI; 2003-156692/15.
DR

PT New breast-specific nucleic acids and polypeptides, useful for
PT identifying, diagnosing, monitoring, staging, imaging, and treating
PT breast cancer and non-cancerous disease states in breast tissues.
XX

PS 1 b; Page 174-175; 269pp; English.
XX
CC The invention relates to breast-specific nucleic acid and polypeptide
CC sequences. The activity of sequences of the invention may be described as
CC cyostatic. The breast-specific nucleic acids, polypeptides and
CC compositions comprising them are useful for identifying, diagnosing,
CC monitoring, staging, imaging, and treating breast cancer and non-
CC cancerous disease states in breast tissue. They are also useful for
CC identifying breast tissue, for monitoring, identifying or designing
CC agonists and antagonists of the polypeptides, in gene therapy, in
CC producing transgenic animals and cells, for producing engineered breast
CC tissue for treatment and research, and as elements in an array or
CC computer program for pattern recognition of breast disorders. The nucleic
CC acids may be used as hybridisation probes to detect, characterise and
CC quantify hybridising nucleic acids in, and isolate hybridising nucleic
CC acids from, both genomic and transcript-derived nucleic acid samples. The
CC sequences given in records ABZ71541-ABZ71693 represent breast-specific
CC nucleic acid sequences of the invention
XX

SQ Sequence 1104 BP; 294 A; 229 C; 293 G; 288 T; 0 U; 0 Other;
Query Match 99.7%; Score 637.4; DB 8; Length 1104;
Best Local Similarity 99.8%; Pred. No. 3.1e-187;
Matches 638; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 CCAGAACCGAGTTTAGGTCAGGTTCTCGTTCTGGCAAAATCTTTCTCCTTACCTTCTTCC 60
Db | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
466 CCAGAACCGAGTTTAGGTCAGGTTCTCGTTCTGGCAAAATCTTTCTCCTTACCTTCTTCC 525
Qy 61 TCACCCCTCACCTATGCAATGTTTCCCTTAGCCACTCCCAAGCTCGGTGGAGGAAG 120
Db | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
526 TCACCCCTCACCTATGCAATGTTTCCCTTAGCCACTCCCAAGCTCGGTGGAGGAAG 585
Qy 121 GCAGGCTTAAGTACCGTCTTCCGACTTTGCTCAATGATAGCTGGGTGGTCTAGC 180
Db | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
586 GCAGGCTTAAGTACCGTCTTCCGACTTTGCTCAATGATAGCTGGGTGGTCTAGC 645
Qy 181 TGGGTTCCAGCCACTTGTAAATGTGGACATCTCTCACCCCAACTTTGTAGTGGAGCAAC 240
Db | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
646 TGGGTTCCAGCCACTTGTAAATGTGGACATCTCTCACCCCAACTTTGTAGTGGAGCAAC 705
Qy 241 TGCTACAGAGTAATATGATTAATCTTACATTCCTTCTGCTGCTCCCAACTTAA 300
Db | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
706 TGCTACAGAGTAATATGATTAATCTTACATTCCTTCTGCTGCTCCCAACTTAA 765
Qy 301 CAGCAGGTAATCTGCTTCTAGCAAGTGGTGAAGTAAGAGAGCATCTGTATAGGAGGCA 360
Db | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
766 CAGCAGGTAATCTGCTTCTAGCAAGTGGTGAAGTAAGAGAGCATCTGTATAGGAGGCA 825
Qy 361 AGAGATCTGAGTCTTTTGAAGGCTATCTCTGCTGTATCTCAATTAATCTGTCTTCA 420
Db | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
826 AGAGATCTGAGTCTTTTGAAGGCTATCTCTGCTGTATCTCAATTAATCTGTCTTCA 885
Qy 421 TTTCAAATATCTTACCTACTATTAATCAGTTCCTTGATCTTTTCTTCTTGGGGCTGCTT 480
Db | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
886 TTTCAAATATCTTACCTACTATTAATCAGTTCCTTGATCTTTTCTTCTTGGGGCTGCTT 945

PR 04-FEB-2000; 2000US-0180628P.
 PR 24-FEB-2000; 2000US-0184664P.
 PR 02-MAR-2000; 2000US-0186350P.
 PR 16-MAR-2000; 2000US-0189874P.
 PR 17-MAR-2000; 2000US-0190076P.
 PR 18-APR-2000; 2000US-0198123P.
 PR 19-MAY-2000; 2000US-020515P.
 PR 07-JUN-2000; 2000US-0209467P.
 PR 28-JUN-2000; 2000US-0214886P.
 PR 30-JUN-2000; 2000US-0215135P.
 PR 07-JUL-2000; 2000US-0216647P.
 PR 07-JUL-2000; 2000US-0216880P.
 PR 11-JUL-2000; 2000US-0217487P.
 PR 11-JUL-2000; 2000US-0217496P.
 PR 14-JUL-2000; 2000US-0218290P.
 PR 26-JUL-2000; 2000US-0220963P.
 PR 26-JUL-2000; 2000US-0220964P.
 PR 14-AUG-2000; 2000US-0224518P.
 PR 14-AUG-2000; 2000US-0224519P.
 PR 14-AUG-2000; 2000US-0225213P.
 PR 14-AUG-2000; 2000US-0225214P.
 PR 14-AUG-2000; 2000US-0225266P.
 PR 14-AUG-2000; 2000US-0225267P.
 PR 14-AUG-2000; 2000US-0225268P.
 PR 14-AUG-2000; 2000US-0225270P.
 PR 14-AUG-2000; 2000US-0225447P.
 PR 14-AUG-2000; 2000US-0225757P.
 PR 14-AUG-2000; 2000US-0225758P.
 PR 14-AUG-2000; 2000US-0225759P.
 PR 18-AUG-2000; 2000US-0226279P.
 PR 22-AUG-2000; 2000US-0226681P.
 PR 22-AUG-2000; 2000US-0226686P.
 PR 22-AUG-2000; 2000US-0227182P.
 PR 23-AUG-2000; 2000US-0227009P.
 PR 30-AUG-2000; 2000US-0228924P.
 PR 01-SEP-2000; 2000US-0229287P.
 PR 01-SEP-2000; 2000US-0229343P.
 PR 01-SEP-2000; 2000US-0229344P.
 PR 01-SEP-2000; 2000US-0229345P.
 PR 05-SEP-2000; 2000US-0229509P.
 PR 05-SEP-2000; 2000US-0229513P.
 PR 06-SEP-2000; 2000US-0230437P.
 PR 08-SEP-2000; 2000US-0231242P.
 PR 08-SEP-2000; 2000US-0231243P.
 PR 08-SEP-2000; 2000US-0231244P.
 PR 08-SEP-2000; 2000US-0231413P.
 PR 08-SEP-2000; 2000US-0231414P.
 PR 08-SEP-2000; 2000US-0232080P.
 PR 12-SEP-2000; 2000US-0231968P.
 PR 14-SEP-2000; 2000US-0232398P.
 PR 14-SEP-2000; 2000US-0232399P.
 PR 14-SEP-2000; 2000US-0232400P.
 PR 14-SEP-2000; 2000US-0232401P.
 PR 14-SEP-2000; 2000US-0233063P.
 PR 14-SEP-2000; 2000US-0233064P.
 PR 14-SEP-2000; 2000US-0233065P.
 PR 21-SEP-2000; 2000US-0234223P.
 PR 21-SEP-2000; 2000US-0234274P.
 PR 25-SEP-2000; 2000US-0234997P.
 PR 25-SEP-2000; 2000US-0234998P.
 PR 26-SEP-2000; 2000US-0235484P.
 PR 27-SEP-2000; 2000US-0235834P.
 PR 27-SEP-2000; 2000US-0235836P.
 PR 29-SEP-2000; 2000US-0236327P.
 PR 29-SEP-2000; 2000US-0236367P.
 PR 29-SEP-2000; 2000US-0236368P.
 PR 29-SEP-2000; 2000US-0236369P.
 PR 29-SEP-2000; 2000US-0236370P.
 PR 02-OCT-2000; 2000US-0236802P.
 PR 02-OCT-2000; 2000US-0237037P.

PR 02-OCT-2000; 2000US-0237038P.
 PR 02-OCT-2000; 2000US-0237039P.
 PR 02-OCT-2000; 2000US-0237040P.
 PR 13-OCT-2000; 2000US-0239915P.
 PR 13-OCT-2000; 2000US-0239937P.
 PR 20-OCT-2000; 2000US-0240960P.
 PR 20-OCT-2000; 2000US-0241221P.
 PR 20-OCT-2000; 2000US-0241785P.
 PR 20-OCT-2000; 2000US-0241786P.
 PR 20-OCT-2000; 2000US-0241787P.
 PR 20-OCT-2000; 2000US-0241808P.
 PR 20-OCT-2000; 2000US-0241809P.
 PR 20-OCT-2000; 2000US-0241826P.
 PR 01-NOV-2000; 2000US-0244617P.
 PR 08-NOV-2000; 2000US-0246474P.
 PR 08-NOV-2000; 2000US-0246475P.
 PR 08-NOV-2000; 2000US-0246476P.
 PR 08-NOV-2000; 2000US-0246477P.
 PR 08-NOV-2000; 2000US-0246478P.
 PR 08-NOV-2000; 2000US-0246523P.
 PR 08-NOV-2000; 2000US-0246524P.
 PR 08-NOV-2000; 2000US-0246525P.
 PR 08-NOV-2000; 2000US-0246526P.
 PR 08-NOV-2000; 2000US-0246527P.
 PR 08-NOV-2000; 2000US-0246528P.
 PR 08-NOV-2000; 2000US-0246532P.
 PR 08-NOV-2000; 2000US-0246609P.
 PR 08-NOV-2000; 2000US-0246610P.
 PR 08-NOV-2000; 2000US-0246611P.
 PR 08-NOV-2000; 2000US-0246613P.
 PR 17-NOV-2000; 2000US-0249207P.
 PR 17-NOV-2000; 2000US-0249208P.
 PR 17-NOV-2000; 2000US-0249209P.
 PR 17-NOV-2000; 2000US-0249210P.
 PR 17-NOV-2000; 2000US-0249211P.
 PR 17-NOV-2000; 2000US-0249212P.
 PR 17-NOV-2000; 2000US-0249213P.
 PR 17-NOV-2000; 2000US-0249214P.
 PR 17-NOV-2000; 2000US-0249215P.
 PR 17-NOV-2000; 2000US-0249216P.
 PR 17-NOV-2000; 2000US-0249217P.
 PR 17-NOV-2000; 2000US-0249218P.
 PR 17-NOV-2000; 2000US-0249244P.
 PR 17-NOV-2000; 2000US-0249245P.
 PR 17-NOV-2000; 2000US-0249264P.
 PR 17-NOV-2000; 2000US-0249265P.
 PR 17-NOV-2000; 2000US-0249277P.
 PR 17-NOV-2000; 2000US-0249299P.
 PR 17-NOV-2000; 2000US-0249300P.
 PR 01-DEC-2000; 2000US-0250160P.
 PR 01-DEC-2000; 2000US-0250391P.
 PR 05-DEC-2000; 2000US-0251030P.
 PR 05-DEC-2000; 2000US-0251988P.
 PR 05-DEC-2000; 2000US-0256719P.
 PR 06-DEC-2000; 2000US-0251479P.
 PR 08-DEC-2000; 2000US-0251856P.
 PR 08-DEC-2000; 2000US-0251868P.
 PR 08-DEC-2000; 2000US-0251869P.
 PR 08-DEC-2000; 2000US-0251989P.
 PR 08-DEC-2000; 2000US-0251990P.
 PR 11-DEC-2000; 2000US-0254097P.
 PR 05-JAN-2001; 2001US-0259678P.
 PR XX (HUMA-) HUMAN GENOME SCI INC.
 PR XX Rosen CA, Barash SC, Ruben SM;
 PI WPI; 2001-502630/55.
 PR XX Polynucleotides encoding digestive system antigens, useful for
 PT diagnosing, treating, preventing and/or prognosing disorders of the
 PT digestive system, particularly cancer and cancer metastases.
 PR XX

PS Disclosure; SEQ ID NO 3074; 986pp; English.

XX The present invention provides the protein and coding sequences of a

CC number of human digestive system antigens. These can be used in the

CC diagnosis, treatment and prevention of digestive system disorders,

CC including cancer, Meckel's diverticulum, bacterial or parasitic

CC infections, appendicitis, Hirschsprung's disease, chronic colitis or

CC ulcerative colitis. The present sequence is a genomic DNA fragment

XX encoding a digestive system antigen of the invention

SQ Sequence 1011 BP; 270 A; 220 C; 248 G; 273 T; 0 U; 0 Other;

Query Match 78.5%; Score 501.8; DB 4; Length 1011;

Best Local Similarity 99.6%; Pred. No. 4.4e-145;

Matches 503; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 CCAGAACCGAGTTTAGGTCAGGTTCTCGTTCTGGCAAAATCTTCTCCTTACCTTCTTCC 60

DB |||||||

QY 482 CCAGAACCGAGTTTAGGTCAGGTTCTCGTTCTGGCAAAATCTTCTCCTTACCTTCTTCC 541

DB |||||||

QY 61 TCCACCCCTCCACCTATGCCATGTTTCCCTTAGCCACTCCCCAGCTCGGTGGAGAAAG 120

DB |||||||

QY 542 TCCACCCCTCCACCTATGCCATGTTTCCCTTAGCCACTCCCCAGCTCGGTGGAGAAAG 601

DB |||||||

QY 121 CGAGGCTTAAGTAGTACGCTTCCGACCTTGTCTCAATGATAGCTGGTGGTCTAGC 180

DB |||||||

QY 602 CGAGGCTTAAGTAGTACGCTTCCGACCTTGTCTCAATGATAGCTGGTGGTCTAGC 661

DB |||||||

QY 181 TGGGTTCCAGCCACTTGAATGTGGGACATCTCTCACCCCAACTTTGTAGTGGAGCAAC 240

DB |||||||

QY 662 TGGGTTCCAGCCACTTGAATGTGGGACATCTCTCACCCCAACTTTGTAGTGGAGCAAC 721

DB |||||||

QY 241 TGCTACAGAGTAATATGATTAACTTTACATTTCCATCTTTCGTCCTCCCAACTTAA 300

DB |||||||

QY 722 TGCTACAGAGTAATATGATTAACTTTACATTTCCATCTTTCGTCCTCCCAACTTAA 781

DB |||||||

QY 301 CAGCAGGTAATCTGCTTCTAGCAAGTGTGAAGTAAGAGCAATCTGTATAGAGGCA 360

DB |||||||

QY 782 CAGCAGGTAATCTGCTTCTAGCAAGTGTGAAGTAAGAGCAATCTGTATAGAGGCA 841

DB |||||||

QY 361 AGAGATCTGAGTCCTTTTGAAGGCTATCTCTGCTCTCAATTAATCTGTTCTTCA 420

DB |||||||

QY 842 AGAGATCTGAGTCCTTTTGAAGGCTATCTCTGCTCTCAATTAATCTGTTCTTCA 901

DB |||||||

QY 421 TTTCAATTATTCTTACTACTATTCAGTTCCCTTGATCTTTTCTTTGGGGCTGCTT 480

DB |||||||

QY 902 TTTCAATTATTCTTACTACTATTCAGTTCCCTTGATCTTTTCTTTGGGGCTGCTT 961

DB |||||||

QY 481 AGGTCAGGAGATTGCAGAGCAC 505

DB |||||||

QY 962 AGGTCAGGAGATTGCAGAGCAC 986

DB |||||||

RESULT 5

AAK87973

ID AAK87973 standard; cDNA; 611 BP.

XX

AC AAK87973;

XX

XX

DT 05-NOV-2001 (first entry)

XX

DE Human digestive system antigen coding sequence SEQ ID NO: 289.

DE

XX

XX Human; digestive system antigen; gene therapy; cancer; appendicitis;

KW ulcerative colitis; infection; Hirschsprung's disease; chronic colitis;

KW digestive system disorder; Meckel's diverticulum; ss.

XX

OS Homo sapiens.

PN

PN WO200155314-A2.

PN

XX

XX 02-AUG-2001.

XX

XX

PF 17-JAN-2001; 2001WO-US001324.

XX

XX 31-JAN-2000; 2000US-0179065P.

PR 04-FEB-2000; 2000US-0180628P.

PR 24-FEB-2000; 2000US-0184664P.

PR 02-MAR-2000; 2000US-0186350P.

PR 16-MAR-2000; 2000US-0189874P.

PR 17-MAR-2000; 2000US-0190076P.

PR 18-APR-2000; 2000US-0198123P.

PR 19-MAY-2000; 2000US-0205515P.

PR 07-JUN-2000; 2000US-0209467P.

PR 28-JUN-2000; 2000US-0214896P.

PR 30-JUN-2000; 2000US-0215135P.

PR 07-JUL-2000; 2000US-0216647P.

PR 07-JUL-2000; 2000US-0216880P.

PR 11-JUL-2000; 2000US-0217487P.

PR 14-JUL-2000; 2000US-0218290P.

PR 26-JUL-2000; 2000US-0220963P.

PR 26-JUL-2000; 2000US-0220964P.

PR 14-AUG-2000; 2000US-0224518P.

PR 14-AUG-2000; 2000US-0224519P.

PR 14-AUG-2000; 2000US-0225213P.

PR 14-AUG-2000; 2000US-0225214P.

PR 14-AUG-2000; 2000US-0225266P.

PR 14-AUG-2000; 2000US-0225267P.

PR 14-AUG-2000; 2000US-0225268P.

PR 14-AUG-2000; 2000US-0225270P.

PR 14-AUG-2000; 2000US-0225447P.

PR 14-AUG-2000; 2000US-0225757P.

PR 14-AUG-2000; 2000US-0225758P.

PR 14-AUG-2000; 2000US-0225759P.

PR 18-AUG-2000; 2000US-0226279P.

PR 22-AUG-2000; 2000US-0226681P.

PR 22-AUG-2000; 2000US-0226868P.

PR 22-AUG-2000; 2000US-0227182P.

PR 23-AUG-2000; 2000US-0227182P.

PR 23-AUG-2000; 2000US-0227009P.

PR 30-AUG-2000; 2000US-0228924P.

PR 01-SEP-2000; 2000US-0229287P.

PR 01-SEP-2000; 2000US-0229343P.

PR 01-SEP-2000; 2000US-0229344P.

PR 01-SEP-2000; 2000US-0229345P.

PR 05-SEP-2000; 2000US-0229509P.

PR 05-SEP-2000; 2000US-0229513P.

PR 06-SEP-2000; 2000US-0230437P.

PR 06-SEP-2000; 2000US-0230438P.

PR 08-SEP-2000; 2000US-0231242P.

PR 08-SEP-2000; 2000US-0231243P.

PR 08-SEP-2000; 2000US-0231244P.

PR 08-SEP-2000; 2000US-0231413P.

PR 08-SEP-2000; 2000US-0231414P.

PR 08-SEP-2000; 2000US-0232080P.

PR 08-SEP-2000; 2000US-0232081P.

PR 12-SEP-2000; 2000US-0231968P.

PR 14-SEP-2000; 2000US-0232397P.

PR 14-SEP-2000; 2000US-0232398P.

PR 14-SEP-2000; 2000US-0232399P.

PR 14-SEP-2000; 2000US-0232400P.

PR 14-SEP-2000; 2000US-0232401P.

PR 14-SEP-2000; 2000US-0233063P.

PR 14-SEP-2000; 2000US-0233064P.

PR 14-SEP-2000; 2000US-0233065P.

PR 21-SEP-2000; 2000US-0234223P.

PR 21-SEP-2000; 2000US-0234274P.

PR 25-SEP-2000; 2000US-0234997P.

PR 25-SEP-2000; 2000US-0234998P.

PR 26-SEP-2000; 2000US-0235484P.

PR 27-SEP-2000; 2000US-0235834P.

PR 27-SEP-2000; 2000US-0235836P.

PR 29-SEP-2000; 2000US-0236327P.

PR 29-SEP-2000; 2000US-0236367P.

PR 29-SEP-2000; 2000US-0236368P.

PR 29-SEP-2000; 2000US-0236369P.

29-SEP-2000; 2000US-0236370P.
PR 02-OCT-2000; 2000US-0236802P.
PR 02-OCT-2000; 2000US-0237037P.
PR 02-OCT-2000; 2000US-0237038P.
PR 02-OCT-2000; 2000US-0237039P.
PR 02-OCT-2000; 2000US-0237040P.
PR 13-OCT-2000; 2000US-0239935P.
PR 13-OCT-2000; 2000US-0239937P.
PR 20-OCT-2000; 2000US-0240960P.
PR 20-OCT-2000; 2000US-0241221P.
PR 20-OCT-2000; 2000US-0241785P.
PR 20-OCT-2000; 2000US-0241786P.
PR 20-OCT-2000; 2000US-0241787P.
PR 20-OCT-2000; 2000US-0241808P.
PR 20-OCT-2000; 2000US-0241809P.
PR 20-OCT-2000; 2000US-0241826P.
PR 01-NOV-2000; 2000US-0244617P.
PR 08-NOV-2000; 2000US-0246474P.
PR 08-NOV-2000; 2000US-0246475P.
PR 08-NOV-2000; 2000US-0246476P.
PR 08-NOV-2000; 2000US-0246477P.
PR 08-NOV-2000; 2000US-0246478P.
PR 08-NOV-2000; 2000US-0246523P.
PR 08-NOV-2000; 2000US-0246524P.
PR 08-NOV-2000; 2000US-0246525P.
PR 08-NOV-2000; 2000US-0246526P.
PR 08-NOV-2000; 2000US-0246527P.
PR 08-NOV-2000; 2000US-0246528P.
PR 08-NOV-2000; 2000US-0246532P.
PR 08-NOV-2000; 2000US-0246609P.
PR 08-NOV-2000; 2000US-0246610P.
PR 08-NOV-2000; 2000US-0246611P.
PR 08-NOV-2000; 2000US-0246613P.
PR 17-NOV-2000; 2000US-0249207P.
PR 17-NOV-2000; 2000US-0249208P.
PR 17-NOV-2000; 2000US-0249209P.
PR 17-NOV-2000; 2000US-0249210P.
PR 17-NOV-2000; 2000US-0249211P.
PR 17-NOV-2000; 2000US-0249212P.
PR 17-NOV-2000; 2000US-0249213P.
PR 17-NOV-2000; 2000US-0249214P.
PR 17-NOV-2000; 2000US-0249215P.
PR 17-NOV-2000; 2000US-0249216P.
PR 17-NOV-2000; 2000US-0249217P.
PR 17-NOV-2000; 2000US-0249218P.
PR 17-NOV-2000; 2000US-0249244P.
PR 17-NOV-2000; 2000US-0249245P.
PR 17-NOV-2000; 2000US-0249264P.
PR 17-NOV-2000; 2000US-0249265P.
PR 17-NOV-2000; 2000US-0249297P.
PR 17-NOV-2000; 2000US-0249299P.
PR 17-NOV-2000; 2000US-0249300P.
PR 01-DEC-2000; 2000US-0250160P.
PR 01-DEC-2000; 2000US-0250391P.
PR 05-DEC-2000; 2000US-0251030P.
PR 05-DEC-2000; 2000US-0251988P.
PR 05-DEC-2000; 2000US-0256719P.
PR 06-DEC-2000; 2000US-0251479P.
PR 08-DEC-2000; 2000US-0251856P.
PR 08-DEC-2000; 2000US-0251868P.
PR 08-DEC-2000; 2000US-0251869P.
PR 08-DEC-2000; 2000US-0251989P.
PR 08-DEC-2000; 2000US-0251990P.
PR 11-DEC-2000; 2000US-0254097P.
PR 05-JAN-2001; 2001US-0259678P.
XX
XX
(HUMA-) HUMAN GENOME SCI INC.
XX
XX Rosen CA, Barash SC, Ruben SM;
XX
XX WPI; 2001-502630/55.
XX
XX P-PSDB; AAM92200.

PT Polynucleotides encoding digestive system antigens, useful for
PT diagnosing, treating, preventing and/or prognosing disorders of the
PT digestive system, particularly cancer and cancer metastases.
XX
XX Claim 1; SEQ ID NO 289; 986pp; English.
XX
CC The present invention provides the protein and coding sequences of a
CC number of human digestive system antigens. These can be used in the
CC diagnosis, treatment and prevention of digestive system disorders,
CC including cancer, Meckel's diverticulum, bacterial or parasitic
CC infections, appendicitis, Hirschsprung's disease, chronic colitis or
CC ulcerative colitis. The present sequence is a cDNA encoding a digestive
CC system antigen of the invention
XX
SQ Sequence 611 BP; 133 A; 144 C; 153 G; 177 T; 0 U; 4 Other;

Query Match 78.0%; Score 498.2; DB 4; Length 611;
Best Local Similarity 98.6%; Pred. No. 4.5e-144;
Matches 555; Conservative 0; Mismatches 3; Indels 5; Gaps 5;

Qy 1 CCAGAACCGAGTTAGTCCAGGTTCCTCGTTCTGGCAAATCTTTCTCTTACCTTCTTCC 60
Db |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Qy 2 CCAGAACCGAGTTAGTCCAGGTTCCTCGTTCTGGCAAATCTTTCTCTTACCTTCTTCC 61
Db |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Qy 61 TCCACCCCTCCACCTATGCCATGTTTTCCCTTAGCCACTCCCCAGCTCGGTGGAGAAAG 120
Db |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Qy 62 TCCACCCCTCCACCTATGCCATGTTTTCCCTTAGCCACTCCCCAGCTCGGTGGAGAAAG 121
Db |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Qy 121 GCAGGCCCTAACTAGGTACCGTCTTCGGGACTTTGCTCAATGATAGCTGGGTGCTTACG 180
Db |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Qy 122 GCAGGCCCTAACTAGGTACCGTCTTCGGGACTTTGCTCAATGATAGCTGGGTGCTTACG 181
Db |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Qy 181 TGGGTTCCAGCCACTTGTATGTGGGACATCTCTCACCCCAACTTTCTAGTGGAGCAAC 240
Db |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Qy 182 TGGGTTCCAGCCACTTGTATGTGGGACATCTCTCACCCCAACTTTCTAGTGGAGCAAC 241
Db |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Qy 241 TGCTACAGAGGTAATATGATTAACATTTTCAATTCATCTTCGTCCTCCCAACTTAA 300
Db |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Qy 242 TGCTACAGAGGTAATATGATTAACATTTTCAATTCATCTTCGTCCTCCCAACTTAA 301
Db |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Qy 301 CAGCAGGTAATCTGC-TTCTAGCAAGTGGTGAAGGTAAGAGAGCATCTGTATAGGAGC 359
Db |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Qy 302 CAGCAGGTAATCTGC-TTCTAGCAAGTGGTGAAGGTAAGAGAGCATCTGTATAGGAGC 361
Db |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Qy 360 AAGAGATCTGAGTCTTTTGAAGGCCCTATCTCTGCTCTGCTCAATTAATCTTCTTC 419
Db |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Qy 362 AAGAGATCTGAGTCTTTTGAAGGCCCTATCTCTGCTCTGCTCAATTAATCTTCTTC 421
Db |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Qy 420 ATTTCAATTATCTTACCTACTATTCAAGTTCCTT-GATCTTTTCTTTGGGGCTGTC 478
Db |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Qy 422 ATTTCAATTATCTTACCTACTATTCAAGTTCCTTGGATCTTTCTTTGGGGCTGTC 481
Db |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Qy 479 TTAGGTCAGGG-AGATTGAGAGACACAGAACTAGGAGAGCCCTGA-GACATGGGA 536
Db |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Qy 482 TTAGGTCAGGGTCGATTGAGAGACACAGAACTAGGAGAGCCCTGAGACATGGGA 541
Db |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Qy 537 G-TTGGAGCTGAAGGAGGATGG 558
Db |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Qy 542 GTTTGGAGCTGAAGGAGGATGG 564
Db |||||||||||||||||||||||||||||||||||||||||||||||||||||||||

RESULT 6
ABZ22025
ID ABZ22025 standard; cDNA; 2360 BP.
XX
XX AC ABZ22025;
XX
XX DT 10-MAR-2003 (first entry)
XX
XX DE Human NIP2 associated protein encoding cDNA SEQ ID NO:3.
XX
XX DR Human; nuclear cap binding protein interacting protein 2; NCBP; NIP2;
XX
XX KW NCBP interacting protein; NIP2 associated protein; NIP2 AP; cancer; gene;

KW	ss.
XX	Homo sapiens.
XX	OS
XX	PH Location/Qualifiers
XX	618..1445
FT	/tag= a
FT	/product= "NIP2 Ap"
XX	CN1343688-A.
PN	
XX	10-APR-2002.
XX	PF 19-SEP-2000; 2000CN-00125281.
XX	PR 19-SEP-2000; 2000CN-00125281.
XX	(SHAN-) SHANGHAI CITY INST TUMORS.
PA	
XX	Gu J, Yang S;
PI	WPI; 2002-548862/59.
DR	P-PSDB; ABP56265.
DR	
XX	Novel human NIP2 associated protein.
PT	
XX	Claim 5; Page 14-16 (Disclosure); 25pp; Chinese.
XX	The present sequence encodes a human nuclear cap binding protein (NCBP)
CC	interacting protein 2 (NIP2) associated protein (I). NIP2 Ap can be used
CC	for treating diseases such as cancer. The present sequence represents a
CC	PCR primer for NIP2 Ap, which is used in an example from the present
CC	invention
XX	
SQ	Sequence 2360 BP; 569 A; 562 C; 621 G; 608 T; 0 U; 0 Other;
	Query Match 54.8%; Score 350.4; DB 6; Length 2360;
	Best Local Similarity 97.0%; Pred. No. 8.2e-98;
	Matches 357; Conservative 0; Mismatches 11; Indels 0; Gaps 0;
QY	228 TAGGTGAGCACTGCTACAGAGTAAATATGATTAACTTTACATTCATCTTTCGTCTG 287
DB	158 TGGGTGAGCACTGCTACAGAGTAAATATGATTAACTTTACATTCATCTTTCGTCTG 217
QY	288 CTCCTAACCTTAACAGCAGTAACTCTCTTAGCAAGTGTTGAAGGTAAGAGAGCATC 347
DB	218 CTCCTAACCTTAACAGCAGTAACTCTCTTAGCAAGTGTTGAAGGTAAGAGAGCATC 277
QY	348 TGATAGGAGCGAAGAGATCTGAGTCTTTTGAAGGCCTATCTCTGCTGTATCTCAA 407
DB	278 TGATAGGAGCGAAGAGATCTGAGTCTTTTGAAGGCCTATCTCTGCTGTATCTCAA 337
QY	408 TTACTGTTCTTCAATTTCAATTTCTTACTACTATTCAGTCCCTTGATCTTTCTTCT 467
DB	338 TTACTGTTCTTCAATTTCAATTTCTTACTACTATTCAGTCCCTTGATCTTTCTTCT 397
QY	468 TGGGGGCTGTTAGGCTCAGGAGATTCAGAGCACACAGAACTAGGAGGAGCCCTGAG 527
DB	398 TGGGGGCTGTTAGGCTCAGGAGATTCAGAGCACACAGAACTAGGAGGAGCCCTGAG 457
QY	528 ACATGGGGAGTTGGAGCTGAAGAGAAATGGCAGGATGAAGAATTCCTTAGGTGAGGACG 587
DB	458 ACATGGGGAGTTGGAGCTGAAGAGAAATGGCAGGATGAAGAATTCCTTAGGTGAGGACG 517
QY	588 TGTGAGGG 595
DB	518 TGAGGAGG 525
RESULT 7	
ID	ABZ71574
XX	ABZ71574 standard; cDNA; 307 BP.

AC	ABZ71574;
XX	
DT	04-APR-2003 (first entry)
XX	
DE	Breast specific nucleic acid # SEQ ID 34.
XX	
KW	Human; breast specific nucleic acid; breast cancer; gene therapy;
KW	cytostatic; ss.
XX	
OS	Homo sapiens.
XX	
PN	WO200288375-A2.
XX	
PD	07-NOV-2002.
XX	
PP	29-OCT-2001; 2001WO-US051318.
XX	
PR	27-OCT-2000; 2000US-0243805P.
XX	
PA	(DIAD-) DIADEXUS INC.
XX	
PI	Sun Y, Recipon H, Salceda S, Liu C, Turner LR;
XX	
DR	WPI; 2003-156692/15.
XX	
PT	New breast-specific nucleic acids and polypeptides, useful for
PT	identifying, diagnosing, monitoring, staging, imaging, and treating
PT	breast cancer and non-cancerous disease states in breast tissues.
XX	
PS	1 b; Page 174; 269pp; English.
XX	
CC	The invention relates to breast-specific nucleic acid and polypeptide
CC	sequences. The activity of sequences of the invention may be described as
CC	cytostatic. The breast-specific nucleic acids, polypeptides and
CC	compositions comprising them are useful for identifying, diagnosing,
CC	monitoring, staging, imaging, and treating breast cancer and non-
CC	cancerous disease states in breast tissue. They are also useful for
CC	identifying breast tissue, for monitoring, identifying or designing
CC	agonists and antagonists of the polypeptides, in gene therapy, in
CC	producing transgenic animals and cells, for producing engineered breast
CC	tissue for treatment and research, and as elements in an array or
CC	computer program for pattern recognition of breast disorders. The nucleic
CC	acids may be used as hybridisation probes to detect, characterise and
CC	quantify hybridising nucleic acids in, and isolate hybridising nucleic
CC	acids from, both genomic and transcript-derived nucleic acid samples. The
CC	sequences given in records ABZ71541-ABZ71693 represent breast-specific
CC	nucleic acid sequences of the invention
XX	
SQ	Sequence 307 BP; 73 A; 53 C; 99 G; 81 T; 0 U; 1 Other;
	Query Match 47.9%; Score 306; DB 8; Length 307;
	Best Local Similarity 99.7%; Pred. No. 1.9e-84;
	Matches 308; Conservative 0; Mismatches 1; Indels 0; Gaps 0
QY	333 GGTAAGAGAGCATCTGTATAGGAGCAAGAGATCTGAGTCCTTTTTGAAGGCCATCTCCTC 392
DB	1 GGTAAGAGAGCATCTGTATAGGAGGCNAGAGATCTGAGTCCTTTTGAAGGCCATCTCCTC 60
QY	393 TGCTCTGTATCTCAATTACTGTCTTCTTCAATTTATTTCTTACCTACTATTTCAGTTCCC 452
DB	61 TGCTCTGTATCTCAATTACTGTCTTCTTCAATTTATTTCTTACCTACTATTTCAGTTCCC 120
QY	453 TTGATCTTTTCTTTGGGGGCTCTTTAGGGTCAGGGAGATTGCGAGAGACCAGAACT 512
DB	121 TTGATCTTTTCTTTGGGGGCTCTTTAGGGTCAGGGAGATTGCGAGAGACCAGAACT 180
QY	513 AGGAGCAGCCCTGAGACATGGGGAGTTGGAGCTGAAGAGAGGAATGCGAGATGAAGAAAT 572
DB	181 AGGAGCAGCCCTGAGACATGGGGAGTTGGAGCTGAAGAGAGGAATGCGAGATGAAGAAAT 240
QY	573 CCTAGGTGAGGACGTGTGAGGGTGTCTGGGAGAGGGGGTGTGTCTACGAATGAGCGG 632
DB	241 CCTAGGTGAGGACGTGTGAGGGTGTCTGGGAGAGGGGGTGTGTCTACGAATGAGCGG 300

```
Qy      633 AGGGGAT 639
      |||||
Db      301 AGGGGAT 307

RESULT 8
ADF85816
ID      ADF85816 standard; cDNA; 307 BP.
XX
XX
AC      ADF85816;
XX
XX      26-FEB-2004 (first entry)
XX
XX      Human breast specific nucleic acid (BSNA) cDNA, SEQ ID NO:34.
XX
XX      Human; breast specific nucleic acid; BSNA; breast cancer; metastasis;
KW      diagnosis; monitoring; staging; imaging; immunotherapy; vaccine;
KW      cytostatic; gene therapy; transgenic animal; tissue engineering; ss.
XX
XX      Homo sapiens.
XX
XX      WO200309989-A2.
XX
XX      04-DEC-2003.
XX
XX      22-MAY-2002; 2002WO-US016307.
XX
XX      22-MAY-2002; 2002WO-US016307.
XX
XX      (DIAD-) DIADEXUS INC.
XX
XX      Sun Y, Recipon H, Salceda S, Liu C, Turner LR;
PI      WPT; 2004-042804/04.
XX
XX      New breast specific nucleic acid molecules and proteins, useful for
PT      identifying, diagnosing, monitoring, staging, imaging and treating breast
PT      cancer and non-cancerous disease states in breast tissue.
XX
XX      Claim 1; SEQ ID NO 34; 269pp; English.
XX
XX      The invention relates to 153 breast specific nucleic acids (BSNA;
CC      ADF85783-ADF85935) and to breast specific proteins (BSP; ADF85936-
CC      ADF86004). The invention also encompasses sequences at least 60%
CC      identical to the BSNA and BSPs of the invention; vectors and host cells
CC      comprising a BSNA; the recombinant production of BSPs using a host cell
CC      comprising a BSNA; an antibody specific for a BSP; methods of detecting
CC      an BSNA or BSP; a method for diagnosing or monitoring the presence and
CC      metastases of breast cancer in a patient; a kit for detecting the risk or
CC      presence of cancer in a patient; a method for the treatment of breast
CC      cancer via the administration of a BSNA or BSP to raise an immune
CC      response against the breast cancer cell expressing the BSNA or BSP; and a
CC      vaccine composition comprising a BSNA or BSP. The BSNA, BSPs, methods
CC      and compositions of the present invention are useful for diagnosing,
CC      monitoring, staging, imaging, and treating breast cancer and breast
CC      cancer metastases, and also non-cancerous disease states in breast
CC      tissue. The BSNA and BSPs are also useful for producing transgenic
CC      animals and cells, for producing engineered breast tissue for treatment
CC      and research, or for identifying breast tissue for breast cell
CC      differentiation and development. The present sequence represents a
CC      specifically claimed breast specific nucleic acid (BSNA). Note: 113 BSPs
CC      are claimed in the invention; however, only 69 of these (ADF85936-
CC      ADF86004) are given in the specification.
XX
XX      Sequence 307 BP; 73 A; 53 C; 99 G; 81 T; 0 U; 1 Other;
SQ

Query Match      47.9%; Score 306; DB 12; Length 307;
Best Local Similarity 99.7%; Pred. No. 1.9e-84;
Matches 306; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

333 GGTAAGAGAGCATCTGTATAGGAGGCNAGAGATCTGAGTCCTTTTGAAGCCCTATCCTC 60
Db      1 GGTAAGAGAGCATCTGTATAGGAGGCNAGAGATCTGAGTCCTTTTGAAGCCCTATCCTC 60
Qy      TGCTCTGTATCTCAATTTACTGTTCTTTCATTTCAATTATTCTTACCTACTATTTCAGTTTCCC 452
      |||||
Db      61 TGCTCTGTATCTCAATTTACTGTTCTTTCATTTCAATTATTCTTACCTACTATTTCAGTTTCCC 120
Qy      TTGATCTTTTCTTCTTGGGGGCTGTCTTAGGGTCAGGGAGATTGCAGAACCCAGAACT 512
      |||||
Db      121 TTGATCTTTTCTTCTTGGGGGCTGTCTTAGGGTCAGGGAGATTGCAGAACCCAGAACT 180
Qy      513 AGGAGAGCCCTGAGACATGGGAGATTGGAGCTGAAGGAGGAATGGCAGGATGAAGATT 572
      |||||
Db      181 AGGAGAGCCCTGAGACATGGGAGATTGGAGCTGAAGGAGGAATGGCAGGATGAAGATT 240
Qy      573 CCTAGGTAGGAGCGTGTGAGGGTGGCTGGGAGAGGGGGTGGTCACGAATGGACGG 632
      |||||
Db      241 CCTAGGTAGGAGCGTGTGAGGGTGGCTGGGAGAGGGGGTGGTCACGAATGGACGG 300
Qy      633 AGGGGAT 639
      |||||
Db      301 AGGGGAT 307

RESULT 9
ADC32261
ID      ADC32261 standard; cDNA; 766 BP.
XX
XX      ADC32261;
AC
XX
XX      18-DEC-2003 (first entry)
DT
XX
XX      Human novel cDNA contig sequence, SEQ ID NO:2343.
DE
XX
XX      Human; diagnostic; drug screening; forensics; gene mapping;
KW      biodiversity assessment; Parkinson's disease; Alzheimer's disease;
KW      neurodegenerative diseases; anaemia; platelet disorder; wound; burns;
KW      ulcers; osteoporosis; autoimmune disease; cancer;
KW      molecular weight marker; food supplement; antiparkinsonian; nootropic;
KW      neuroprotective; antianemic; anticoagulant; thrombolytic; vulnery;
KW      antiulcer; osteopathic; immunosuppressive; antiinflammatory; cytostatic;
KW      gene therapy; ss.
XX
XX      Homo sapiens.
OS
XX
XX      WO2003029271-A2.
PN
XX
XX      10-APR-2003.
PD
XX
XX      24-SEP-2002; 2002WO-US030474.
PF
XX
XX      24-SEP-2001; 2001US-0324631P.
PR
XX
XX      (HYSE-) HYSEQ INC.
PA
XX
XX      Tang TY, Zhang J, Ren F, Xue AJ, Zhao QA, Wang J, Wehrman T;
PI      Zhou P, Ghosh M, Wang D, Ma Y, Asundi V, Wang Z, Weng G;
PI      Haley-Vicente D, Drmanac RT;
XX
XX      WPI; 2003-371981/35.
DR
XX
XX      P-PSDB; ADC33028.
DR
XX
XX      New polynucleotide and polypeptide useful for diagnosing, preventing or
PT      treating conditions such as neurodegenerative diseases, anemias, platelet
PT      disorders, wounds, burns, ulcers, osteoporosis, autoimmune diseases or
PT      cancer.
XX
XX      Example 2; SEQ ID NO 2343; 1185pp; English.
PS
XX
XX      The invention relates to 971 novel human cDNA sequences (ADC29919-
CC      ADC30889) and the polypeptides they encode (ADC30890-ADC31860). The
CC      invention also relates to nucleic acid sequences over 99% identical with
CC      the novel human cDNAs. The invention additionally encompasses expression
CC      vectors and host cells comprising a nucleic acid of the invention; the
```


KW Human; ss; gene; pharmaceutical; diagnostic; gene therapy; tissue regeneration; cell regeneration; membrane protein; signal transduction-related protein; transcription-related protein; osteoporosis; neurological disease; cancer; tumour.

XX Homo sapiens.

XX Key Location/Qualifiers

XX CDS 126..1199

XX FT /*tag= a

XX FT /product= "Clone PROST20063430 protein"

XX PN EP1308459-A2.

XX PD 07-MAY-2003.

XX PF 28-MAR-2002; 2002EP-00007401.

XX PR 05-NOV-2001; 2001JP-00379298.

XX PR 25-JAN-2002; 2002US-00350978.

XX PA (HELI-) HELIX RES INST.

XX PA (REAS-) RES ASSOC BIOTECHNOLOGY.

XX PI Isogai T, Sugiyama T, Otsuki T, Wakamatsu A, Sato H, Ishii S;

XX PI Yamamoto J, Isono Y, Hio Y, Otsuka K, Nagai K, Tamechika I;

XX PI Seki N, Yoshikawa T, Otsuka M, Nagahari K, Masuho Y;

XX DR WPI; 2003-450961/43.

XX DR P-PSDB; ADB64961.

XX PT New polynucleotides and polypeptides, useful for developing a diagnostic marker or medicines for regulation of their expression and activity, or as targets of gene therapy.

XX PS Claim 1; Page: 222pp; English.

XX CC The invention discloses a polynucleotide comprising a sequence selected from 1970 fully defined nucleotide sequences which encode novel polypeptides. Also claimed is a polypeptide encoded by the polynucleotide or its partial peptide, an antibody binding to the polypeptide or peptide of the polynucleotide, immunologically assaying the polypeptide or peptide of the polynucleotide by contacting the polypeptide or peptide with the antibody of the encoded protein, and observing the binding between the two, a transformant carrying the polynucleotide in an expressible manner and an antisense polynucleotide. The oligonucleotide is useful as a primer for synthesising the polynucleotide, or as a probe for detecting the polynucleotide. The polynucleotides and encoded proteins are useful as pharmaceutical agents and many disease-related genes may be included in them, for developing a diagnostic marker or medicines for regulation of their expression and activity, or as targets of gene therapy. The genes are involved in tissue and/or cell regeneration. Membrane proteins, signal transduction-related proteins, transcription-related proteins, disease-related proteins and genes encoding them can be used as indicators for diseases (e.g. osteoporosis, neurological diseases, cancer, tumours). The cDNA may be used to regulate the activity or expression of the encoded protein to treat diseases. The sequence presented is a cDNA of the invention. Note: Some of the sequence data for this patent is not represented in the printed specification, but is based on sequence information supplied by the European Patent Office.

XX SQ Sequence 2112 BP; 497 A; 515 C; 573 G; 527 T; 0 U; 0 Other;

Query Match 15.6%; Score 99.8; DB 10; Length 2112;

Best Local Similarity 89.9%; Pred. No. 6.7e-20;

Matches 107; Conservative 0; Mismatches 12; Indels 0; Gaps 0;

QY 477 TCTTAGGCTCAGGAGATTGCAGAACGACACAGACTAGGAGCAGCCCTGACATGGGGA 536

DB 161 TGTGGGGTCAGGAGATTGCAGAACGACACAGACTAGGAGCAGCCCTGACATGGGGA 220

QY 537 GTTGAGCTGAAGGAGGAATGGCAGGATGAAGAAATTCCTAGGTGAGGACGTGTGAGG 595

|||||

Db 221 GTTGGAGCTGAAGGAGGAATGGCAGGATGAAGAAATTCCTAGATTGCTTCTCTGAGGAGG 279

RESULT 12

ACN92793/c

ID ACN92793 standard; DNA; 503 BP.

XX AC ACN92793;

XX DT 02-DEC-2004 (first entry)

XX DE Breast cancer related marker, seq id 13943.

XX KW Cancer; breast; tumour; cytostatic; marker; detection; therapy; ds.

XX OS Homo sapiens.

XX PN US2003099974-A1.

XX PD 29-MAY-2003.

XX PF 18-JUL-2002; 2002US-00198846.

XX PR 18-JUL-2001; 2001US-0306220P.

XX PA (MILL-) MILLENNIUM PHARM INC.

XX PI Lillie J, Xu Y, Wang Y, Steinmann K;

XX DR WPI; 2003-787014/74.

XX PT Novel isolated polypeptide associated with breast cancer, useful for detecting presence of polypeptide in sample, as a marker for breast cancer.

XX PS Disclosure; SEQ ID NO 13943; 36pp; English.

XX CC The invention relates to an isolated polypeptide (I) associated with breast cancer which is encoded by a nucleic acid molecule comprising a nucleotide sequence (S1). Further disclosed is an antibody that binds to the polypeptide of the invention. The activity of the polypeptide of the invention may be described as cytostatic. The antibody is useful for detecting the presence of (I) in a sample. Nucleic acid molecules of the invention are useful in the detection of breast tumours. (I) is useful as a marker for breast cancer and in breast cancer therapy. Sequences given in records ACN78851-ACN92934 represent nucleic acid markers associated with breast cancer. Note: The sequence listing does not form part of the specification but may be obtained in electronic format from the USPTO web site at seqdata.uspto.gov/sequence.html?DocID=20030099974

XX SQ Sequence 503 BP; 126 A; 134 C; 104 G; 134 T; 0 U; 5 Other;

Query Match 11.9%; Score 75.8; DB 11; Length 503;

Best Local Similarity 97.5%; Pred. No. 9.5e-13;

Matches 77; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 561 GGATGAAGAAATTCCTAGGTGAGGAGCGTGTGAGGGTGGTGAGGAGGAGGGGTGCTC 620

DB 499 GGATGAAGAAATTCCTAGGTGAGGAGCGTGTGAGGGTGGTGAGGAGGAGGGGTGCTC 440

QY 621 ACGAATGGACGGAGGGAT 639

DB 439 ACGAATGGACGGAGGGAT 421

RESULT 13

ACN44504

ID ACN44504 standard; DNA; 202251 BP.

XX AC ACN44504;

XX DT 18-NOV-2004 (first entry)

XX

DE Mouse genomic sequence MCG20408.
KW Cytostatic; carcinoma; lymphoma; cancer; murine; gene; ss.
XX Mus musculus.
OS WO2003073826-A2.
PN 12-SEP-2003.
XX 28-FEB-2003; 2003WO-US006235.
XX 01-MAR-2002; 2002US-00087192.
XX (SAGR-) SAGRES DISCOVERY.
XX Morris DW;
XX WPI; 2003-328604/31.
XX Recombinant nucleic acid useful for diagnosis and treatment of carcinoma
PT comprises a nucleotide sequence.
PT Claim 1; SEQ ID NO 985; Opp; English.
XX The present invention relates to novel DNA and protein sequences which
CC are associated with carcinomas. The sequences are useful for: (i) for
CC screening drug candidates; (ii) for screening of bioactive agent capable
CC of binding to Carcinoma Associated Protein (CAP); (iii) for screening of
CC a bioactive agent capable of modulating the activity of CAP; (iv) for
CC evaluating the effect of a candidate carcinoma drug; (v) for diagnosing
CC carcinoma; (vi) for inhibiting the activity of CAP; (vii) for treating
CC carcinoma; (viii) for neutralizing the effect of CAP; (ix) as a biochip;
CC (x) for diagnosing carcinoma or a propensity to carcinoma; and (xi) for
CC determining Carcinoma Associated (CA) gene copy number. In addition, the
CC CA genes are useful as DNA vaccines and the CAP are useful as markers of
CC carcinoma including lymphoma. The present sequence is one such CA coding
CC sequence. Note: This patent is an equivalent to basic patent
CC US2002182586A1, for which no sequence data was published
XX
SQ Sequence 202251 BP; 51742 A; 46659 C; 46432 G; 53759 T; 0 U; 3659 Other;
Query Match 7.1%; Score 45.2; DB 11; Length 202251;
Best Local Similarity 52.7%; Pred. No. 0.064;
Matches 98; Conservative 0; Mismatches 88; Indels 0; Gaps 0;
QY 452 CTGATCTTTTCTTCTTGGGGCTGCTTAGGGTCAGGAGATTGCAGAACACCAGAAC 511
DB 140383 CCTGACATTGGACCTTGGGAGACAGAGATCAGTAGCAGCAGCAGCAGCAG 140442
QY 512 TAGGAGCAGCCCTGAGACATGGGGAGTTGGAGCTGAAGGAGGAATGGCAGGATGAAGAAT 571
DB 140443 CAGCAGGAGAAAGAGAGAGAGGGGGAAGGAGAGAGAGAGAGAGAGAGAGAGAG 140502
QY 572 TCCCTAGGTAGGACGTGTAGGGTGGCTGGGAGAGGAGGGGTGGTCAAGATGGACG 631
DB 140503 AAGCAGGAGAGAGAGAGAGAGGGGGAAGGAGAGAGAGAGAGAGAGAGAGAGAG 140562
QY 632 GAGGGG 637
DB 140563 AAGAGG 140568
RESULT 14
AAD30228/c
ID AAD30228 standard; DNA; 53522 BP.
XX
AC AAD30228;
XX
DT 17-MAY-2002 (first entry)
XX
DE Human PKD1 gene.
XX
KW Human; PKD1 gene; autosomal dominant polycystic kidney disease; ADPKD;
XX acquired cystic disease; transgenic animal; chromosome 16; ds.
XX Homo sapiens.
OS WO200206529-A2.
PN 24-JAN-2002.
XX 13-JUL-2001; 2001WO-US022035.
XX 13-JUL-2000; 2000US-0218261P.
XX 13-APR-2001; 2001US-0283691P.
XX (UYJO) UNIV JOHNS HOPKINS SCHOOL MEDICINE.
XX Germino GG, Watnick TJ, Phakdeekitcharoen B;
XX WPI; 2002-179805/23.
XX Novel primer for diagnosing polycystic kidney disease-associated
PT disorder, comprises regions having sequence that selectively hybridizes
PT to polycystic kidney disease gene sequence.
XX
PS Claim 20; Page 127-156; 192pp; English.
XX The present invention relates to compositions and methods useful for the
CC identification and detection of polycystic kidney disease (PKD1) gene
CC mutations. The invention also relates to primers comprising a 5' region
CC having a sequence that selectively hybridizes to a PKD1 gene sequence and
CC optionally, to a PKD1 homologue sequence and an adjacent 3' region having
CC a sequence that selectively hybridizes to a PKD1 gene sequence and not to
CC a PKD1 homologue sequence. Primer pairs of the invention are useful for
CC detecting the presence or absence of a mutation in a PKD1 polynucleotide
CC in a sample, for identifying a subject at risk for a PKD1-associated
CC disorder such as autosomal dominant polycystic kidney disease (ADPKD) or
CC acquired cystic disease and for diagnosing a PKD1-associated disorder in
CC a subject. They are useful for selectively amplifying a region of a PKD1
CC gene. PKD1 DNA fragments are useful for detecting the presence of a mutant
CC PKD1 polynucleotide in a sample, as a probe for an amplification
CC reaction, in hybridisation or amplification assays of biological samples
CC to detect abnormalities of PKD1 expression and for engineering transgenic
CC animals. The present sequence is human PKD1 gene located on chromosome 16
XX
SQ Sequence 53522 BP; 8486 A; 17664 C; 15766 G; 11606 T; 0 U; 0 Other;
Query Match 6.6%; Score 42; DB 6; Length 53522;
Best Local Similarity 52.9%; Pred. No. 0.32;
Matches 90; Conservative 0; Mismatches 80; Indels 0; Gaps 0;
QY 469 GGGGGCTGCTTTAGGGTCAGGAGATTGCAGAACCCAGAACCTTAGGAGCAGCCCTGAGA 528
DB 34691 GCGGAGGGGAGGAGGGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 34632
QY 529 CATGGGAGTTGGAGCTGAAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 588
DB 34631 GAGGAGGGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 34572
QY 589 GTGAGGGTGGCTGGGAGAAAGGGGGTGGTTCACGAATGGACGGAGGGGA 638
DB 34571 GAGGAGGGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 34522
RESULT 15
AAT94101/c
ID AAT94101 standard; DNA; 53526 BP.
XX
AC AAT94101;
XX
DT 25-MAR-2003 (revised)
XX
DT 01-JUN-1998 (first entry)
XX
DE Human PKD1 gene.
XX

GenCore version 5.1.6
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: October 12, 2005, 09:32:49 ; Search time 168 Seconds
(without alignments)
6223.695 Million cell updates/sec

Title: US-09-721-183-4

Perfect score: 639

Sequence: 1 ccagaacgagtttagtcc.....cacgaatggacggaggggat 639

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 1202784 seqs, 818138359 residues

Total number of hits satisfying chosen parameters: 2405568

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Issued Patents NA.*
1: /cgn2_6/ptodata/1/ina/5A COMB.seq.*
2: /cgn2_6/ptodata/1/ina/5B COMB.seq.*
3: /cgn2_6/ptodata/1/ina/6A COMB.seq.*
4: /cgn2_6/ptodata/1/ina/6B COMB.seq.*
5: /cgn2_6/ptodata/1/ina/PTUS COMB.seq.*
6: /cgn2_6/ptodata/1/ina/backfiles1.seq.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
C 1	45.2	7.1	7218	1	US-08-232-463-14
C 2	42	6.6	53526	3	US-08-658-136-2
C 3	42	6.6	53577	3	US-08-658-136-1
C 4	39.8	6.2	7218	1	US-08-232-463-14
C 5	38.2	6.0	8279	4	US-09-949-016-13478
C 6	37.2	5.8	1038	3	US-08-031-148-3
C 7	37.2	5.8	1038	3	US-08-415-838-3
C 8	37.2	5.8	1038	3	US-09-205-169-3
C 9	36.4	5.7	79350	4	US-09-949-016-12467
C 10	36.4	5.7	79351	4	US-09-949-016-16275
C 11	36.4	5.7	247781	4	US-09-949-016-14193
C 12	36.2	5.7	149971	4	US-09-949-016-13590
C 13	36	5.6	462	4	US-09-621-976-15621
C 14	35.4	5.5	120727	4	US-09-949-016-15787
C 15	35.4	5.5	120727	4	US-09-949-016-15788
C 16	35.2	5.5	18955	4	US-09-949-016-13343
C 17	35.2	5.5	30678	4	US-09-949-016-12818
C 18	34.8	5.4	500	4	US-09-866-108A-15742
C 19	34.8	5.4	1141	4	US-09-806-708B-22
C 20	34.8	5.4	231129	4	US-09-949-016-16110
C 21	34.8	5.4	262293	4	US-09-949-016-11934
C 22	34.6	5.4	9052	4	US-09-949-016-13662
C 23	34.6	5.4	23802	4	US-09-949-016-12107
C 24	34.6	5.4	23803	4	US-09-949-016-15878
C 25	34.6	5.4	174029	4	US-09-949-016-12610
C 26	34.6	5.4	174030	4	US-09-949-016-13880
C 27	34.4	5.4	289	3	US-09-007-005-17

28	34.4	5.4	289	3	US-09-244-796-17	Sequence 17, Appl
29	34.4	5.4	3614	4	US-09-221-013A-9	Sequence 9, Appl
30	34.2	5.4	601	4	US-09-949-016-103065	Sequence 103065,
31	34.2	5.4	601	4	US-09-949-016-103140	Sequence 103140,
32	34.2	5.4	601	4	US-09-949-016-187952	Sequence 187952,
33	34.2	5.4	15907	4	US-09-949-016-16818	Sequence 16818, A
34	34.2	5.4	300598	4	US-09-949-016-11868	Sequence 11868, A
35	34.2	5.4	302604	4	US-09-949-016-14588	Sequence 14588, A
36	34.2	5.4	302604	4	US-09-949-016-14589	Sequence 14589, A
37	34.2	5.4	308362	4	US-09-949-016-17119	Sequence 17119, A
38	34	5.3	6585	4	US-09-949-016-14470	Sequence 14470, A
C 39	33.8	5.3	3293	4	US-09-949-016-4658	Sequence 4658, App
C 40	33.8	5.3	3314	4	US-09-949-016-836	Sequence 836, App
C 41	33.8	5.3	4544	4	US-08-956-171E-517	Sequence 517, App
C 42	33.8	5.3	4544	4	US-08-781-986A-517	Sequence 517, App
C 43	33.8	5.3	31440	4	US-09-949-016-12578	Sequence 12578, A
C 44	33.8	5.3	31444	4	US-09-949-016-16400	Sequence 16400, A
C 45	33.8	5.3	78649	4	US-09-949-016-14619	Sequence 14619, A

ALIGNMENTS

RESULT 1
US-08-232-463-14/c
; Sequence 14, Application US/08232463
; Patent No. 5670367
; GENERAL INFORMATION:
; APPLICANT: DORNER, P.
; APPLICANT: SCHEIFLINGER, F.
; APPLICANT: FALKNER, F. G.
; TITLE OF INVENTION: RECOMBINANT FOWLPOX VIRUS
; NUMBER OF SEQUENCES: 52
; CORRESPONDENCE ADDRESS:
; ADDRESS: Foley & Lardner
; STREET: 1800 Diagonal Road, Suite 500
; CITY: Alexandria
; STATE: VA
; COUNTRY: USA
; ZIP: 22313-0299
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/232,463
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/07/935,313
; FILING DATE:
; APPLICATION NUMBER: EP 91 114 300.6
; FILING DATE: 26-AUG-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: BENT, Stephen A.
; REGISTRATION NUMBER: 29,768
; REFERENCE/DOCKET NUMBER: 30472/114 IMMU
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (703)836-9300
; TELEFAX: (703)683-4109
; TELEX: 899149
; INFORMATION FOR SEQ ID NO: 14:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 7218 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; IMMEDIATE SOURCE:
; CLONE: pTZgpt-F1s
US-08-232-463-14

Query Match 7.1%; Score 45.2; DB 1; Length 7218;


```

; GENERAL INFORMATION:
; APPLICANT: DORNER, F.
; APPLICANT: SCHEIFLINGER, F.
; APPLICANT: FALKNER, F. G.
; TITLE OF INVENTION: RECOMBINANT FOWLPOX VIRUS
; NUMBER OF SEQUENCES: 52
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Foley & Lardner
; STREET: 1800 Diagonal Road, Suite 500
; CITY: Alexandria
; STATE: VA
; COUNTRY: USA
; ZIP: 22313-0299
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/232.463
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/07/935.313
; FILING DATE:
; APPLICATION NUMBER: EP 91 114 300.6
; FILING DATE: 26-AUG-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: BENT, Stephen A.
; REGISTRATION NUMBER: 29,768
; REFERENCE/DOCKET NUMBER: 30472/114 IMMU
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (703)836-9300
; TELEFAX: (703)683-4109
; TELEX: 899149
; INFORMATION FOR SEQ ID NO: 14:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 7218 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; IMMEDIATE SOURCE:
; CLONE: pTZgpt-F18
;
US-08-232-463-14
Query Match 6.2%; Score 39.8; DB 1; Length 7218;
Best Local Similarity 5.4%; Pred. No. 0.12;
Matches 17; Conservative 167; Mismatches 129; Indels 0; Gaps 0;

Qy 7 CCGAGTTTAGTCCAGGTTCTCGTTCTCGCAAAATCTTCTCTACCTTCTTCTCCACC 66
Db 1033 CCGAGTTTAGTCCAGGTTCTCGTTCTCGCAAAATCTTCTCTACCTTCTTCTCCACC 66
Qy 67 CCTCACCTATGCCATGTTTCCCTTAGCCACTCCAGCTCCGTTGGAGGAAGCAGGC 126
Db 1093 YYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYY 1152
Qy 127 CTAAGTAGTACCGCTCTCCGACTTTCTGCTCAATGATAGCTGGGTGGGTCTAGCTGGGTT 186
Db 1153 YYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYY 1212
Qy 187 CCAGCCACTTGAATGTGGGACATCTCTCACCCCAACTTTGTAGGTGAGCAACTGTCTAC 246
Db 1213 YYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYY 1272
Qy 247 AGAGTAATATGATTAATCTTACATTCATCTTCTGCTGCTCCCAACTTACAGCAG 306
Db 1273 YYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYY 1332
Qy 307 GTAATCTGCTTCT 319
Db 1333 YYYYYYYYYYYY 1345

RESULT 5
US-09-949-016-13478
; Sequence 13478, Application US/09949016
; Patent No. 6812339
; GENERAL INFORMATION:
; APPLICANT: VENTER, J. Craig et al.
; TITLE OF INVENTION: POLYMORPHISMS IN KNOWN GENES ASSOCIATED
; FILE REFERENCE: WITH HUMAN DISEASE, METHODS OF DETECTION AND USES THEREOF
; FILE REFERENCE: CLO01307
; CURRENT APPLICATION NUMBER: US/09/949,016
; CURRENT FILING DATE: 2000-04-14
; PRIOR APPLICATION NUMBER: 60/241,755
; PRIOR FILING DATE: 2000-10-20
; PRIOR APPLICATION NUMBER: 60/237,768
; PRIOR FILING DATE: 2000-10-03
; PRIOR APPLICATION NUMBER: 60/231,498
; PRIOR FILING DATE: 2000-09-08
; NUMBER OF SEQ ID NOS: 207012
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 13478
; LENGTH: 8279
; TYPE: DNA
; ORGANISM: Human
;
US-09-949-016-13478
Query Match 6.0%; Score 38.2; DB 4; Length 8279;
Best Local Similarity 52.1%; Pred. No. 0.42;
Matches 85; Conservative 0; Mismatches 78; Indels 0; Gaps 0;

Qy 469 GGGGGCTGCTTCTTAGGTCAGGAGATTCCAGAAGCACCAGAACTAGGAGCAGCCCTGAGA 528
Db 1215 GGGGGCATAGGTGTGGAAGGGGTGGGGAAGAGGGGCCAGGAGTGGGTGGAAGAGGGG 1274
Qy 529 CATGGGAGTTGGAGCTGAAGGAGGAATGGCAGGATGAAGAAATTCCTTAGGTGAGGACGT 588
Db 1275 AAAGAAGAGGATAGGAGGACAGGACAGGAGAGGCCAGGATGGTAGGAGGGAAGA 1334
Qy 589 GTGAGGTGGCTGGGAGAAAGGGAGGGGTGGTCACGAATGGAGC 631
Db 1335 CAGAGGAGGGGGGACGAGGGGGCGGATGAAGAGGGGGCG 1377

RESULT 6
US-08-031-148-3/c
; Sequence 3, Application US/08031148
; Patent No. 5424398
; GENERAL INFORMATION:
; APPLICANT: Middelorp, Jaap Michiel..
; TITLE OF INVENTION: Peptides and nucleic acid sequences
; TITLE OF INVENTION: related to the Epstein-Barr virus.
; NUMBER OF SEQUENCES: 22
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Akzo Pharma
; STREET: 1330-A Piccard Drive
; CITY: Rockville
; STATE: Maryland
; COUNTRY: USA
; ZIP: 20850-4377
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/031.148
; FILING DATE: 19930312
; CLASSIFICATION: 530
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: EP 92200721.6
; FILING DATE: 13-MAR-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Bobrowicz, Donna

```

	;	REGISTRATION NUMBER:	32,196	
	;	INFORMATION FOR SEQ ID NO:	3:	
	;	SEQUENCE CHARACTERISTICS:		
	;	LENGTH:	1038 base pairs	
	;	TYPE:	NUCLEIC ACID	
	;	STRANDEDNESS:	double	
	;	TOPOLOGY:	unknown	
	;	MOLECULE TYPE:	DNA (genomic)	
	;	ORIGINAL SOURCE:		
	;	ORGANISM:	Epstein-Barr virus	
	US-08-031-148-3			
		Query Match	5.8%; Score 37.2; DB 1; Length 1038;	
		Best Local Similarity	52.6%; Pred. No. 0.27;	
		Matches	81; Conservative 0; Mismatches 73; Indels 0; Gaps 0;	
Qy	457	TCCTTTTCTTTCTGGGGGCTGTCTTAGGGTCAGGGAGATTGCAGAAGCACCAACTAGGA	516	
Db	468	TCCTTTCCCGCTTGTTGGATCGCAGGACGGGGACGTAGTCTGCCCGCAAGTGGGATCC	409	
Qy	517	GCAGCCCTGAGACATCGGGAGTTGGAGCTGAAGGAGGAATGCGACGATGAAGAATTCCT	576	
Db	408	GTAAGGAGGACCGGTGGAGGGGGCCAAAGAGGCCCGGCAAGCAAGTAGGCGG	349	
Qy	577	AGGTAGGACGTGTGAGGTGCTGGGAGAGGG	610	
Db	348	AGGGGGGTGTGGTGGGGTGTGAGTGTGAGCG	315	
	RESULT 7			
	US-08-415-838-3/c			
	;	Sequence 3, Application US/08415838		
	;	Patent No. 6008327		
	;	GENERAL INFORMATION:		
	;	APPLICANT: Middeldorp, Jaap Michiel.		
	;	TITLE OF INVENTION: Peptides and nucleic acid sequences		
	;	related to the Epstein-Barr virus.		
	;	NUMBER OF SEQUENCES: 22		
	;	CORRESPONDENCE ADDRESS:		
	;	ADDRESSEE: Akzo-No. 6008327el Patent Department		
	;	STREET: 1300 Piccard Drive, Suite 206		
	;	CITY: Rockville		
	;	STATE: Maryland		
	;	COUNTRY: USA		
	;	ZIP: 20850		
	;	COMPUTER READABLE FORM:		
	;	MEDIUM TYPE: Floppy disk		
	;	OPERATING SYSTEM: PC-DOS/MS-DOS		
	;	SOFTWARE: Patentin Release #1.0, Version #1.25		
	;	CURRENT APPLICATION DATA:		
	;	PRIOR APPLICATION NUMBER: EP 92200721.6		
	;	FILING DATE: 13-MAR-1992		
	;	ATTORNEY/AGENT INFORMATION:		
	;	NAME: Gormley, Mary E.		
	;	REGISTRATION NUMBER: 34,409		
	;	INFORMATION FOR SEQ ID NO: 3:		
	;	SEQUENCE CHARACTERISTICS:		
	;	LENGTH: 1038 base pairs		
	;	TYPE: nucleic acid		
	;	STRANDEDNESS: double		
	;	TOPOLOGY: unknown		
	;	MOLECULE TYPE: DNA (genomic)		
	;	ORIGINAL SOURCE:		
	;	ORGANISM: Epstein-Barr virus		
	;	SEQUENCE DESCRIPTION: SEQ ID NO: 3:		
	US-08-415-838-3			
		Query Match	5.8%; Score 37.2; DB 3; Length 1038;	
		Best Local Similarity	52.6%; Pred. No. 0.27;	
		Matches	81; Conservative 0; Mismatches 73; Indels 0; Gaps 0;	
Qy	457	TCCTTTTCTTTCTGGGGGCTGTCTTAGGGTCAGGGAGATTGCAGAAGCACCAACTAGGA	516	
Db	468	TCCTTTCCCGCTTGTTGGATCGCAGGACGGGGACGTAGTCTGCCCGCAAGTGGGATCC	409	
Qy	517	GCAGCCCTGAGACATCGGGAGTTGGAGCTGAAGGAGGAATGCGACGATGAAGAATTCCT	576	
Db	408	GTAAGGAGGACCGGTGGAGGGGGCCAAAGAGGCCCGGCAAGCAAGTAGGCGG	349	
Qy	577	AGGTAGGACGTGTGAGGTGCTGGGAGAGGG	610	
Db	348	AGGGGGGTGTGGTGGGGTGTGAGTGTGAGCG	315	
	RESULT 8			
	US-09-205-169-3/c			
	;	Sequence 3, Application US/09205169		
	;	Patent No. 6365717		
	;	GENERAL INFORMATION:		
	;	APPLICANT: Middeldorp, Jaap Michiel.		
	;	TITLE OF INVENTION: Peptides and nucleic acid sequences		
	;	related to the Epstein-Barr virus.		
	;	NUMBER OF SEQUENCES: 22		
	;	CORRESPONDENCE ADDRESS:		
	;	ADDRESSEE: Akzo-No. 6365717el Patent Department		
	;	STREET: 1300 Piccard Drive, Suite 206		
	;	CITY: Rockville		
	;	STATE: Maryland		
	;	COUNTRY: USA		
	;	ZIP: 20850		
	;	COMPUTER READABLE FORM:		
	;	MEDIUM TYPE: Floppy disk		
	;	OPERATING SYSTEM: IBM PC compatible		
	;	SOFTWARE: Patentin Release #1.0, Version #1.25		
	;	CURRENT APPLICATION DATA:		
	;	PRIOR APPLICATION NUMBER: US/09/205,169		
	;	FILING DATE: 04-Dec-1998		
	;	APPLICATION DATA:		
	;	APPLICATION NUMBER: 08/415,838		
	;	FILING DATE: <Unknown>		
	;	ATTORNEY/AGENT INFORMATION:		
	;	NAME: Gormley, Mary E.		
	;	REGISTRATION NUMBER: 34,409		
	;	INFORMATION FOR SEQ ID NO: 3:		
	;	SEQUENCE CHARACTERISTICS:		
	;	LENGTH: 1038 base pairs		
	;	TYPE: nucleic acid		
	;	STRANDEDNESS: double		
	;	TOPOLOGY: unknown		
	;	MOLECULE TYPE: DNA (genomic)		
	;	ORIGINAL SOURCE:		
	;	ORGANISM: Epstein-Barr virus		
	;	SEQUENCE DESCRIPTION: SEQ ID NO: 3:		
	US-09-205-169-3			
		Query Match	5.8%; Score 37.2; DB 3; Length 1038;	

RESULT 9

US-09-949-016-12467/c
; Sequence 12467, Application US/09949016
; Patent No. 6812339
; GENERAL INFORMATION:
; APPLICANT: VENTER, J. Craig et al.
; TITLE OF INVENTION: POLYMORPHISMS IN KNOWN GENES ASSOCIATED
; WITH HUMAN DISEASE, METHODS OF DETECTION AND USES THEREOF
; FILE REFERENCE: CL001307
; CURRENT APPLICATION NUMBER: US/09/949,016
; CURRENT FILING DATE: 2000-04-14
; PRIOR APPLICATION NUMBER: 60/241,755
; PRIOR FILING DATE: 2000-10-20
; PRIOR APPLICATION NUMBER: 60/237,768
; PRIOR FILING DATE: 2000-10-03
; PRIOR APPLICATION NUMBER: 60/231,498
; PRIOR FILING DATE: 2000-09-08
; NUMBER OF SEQ ID NOS: 207012
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 12467
; LENGTH: 79350
; TYPE: DNA
; ORGANISM: Human
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)...(79350)
; OTHER INFORMATION: n = A,T,C or G

US-09-949-016-12467

Query Match 5.7%; Score 36.4; DB 4; Length 79350;
Best Local Similarity 55.6%; Pred. No. 5.6;
Matches 70; Conservative 0; Mismatches 56; Indels 0; Gaps 0;

Qy 351 ATAGAGGCAAGATCTGAGTCCTTTTGAAGGCTATCCCTGCTGTCTGTATCTCAATTA 410
Db 65064 AAAGGAACAGAGATGTCAAGAGAGAGAGGATGTGTGTCTCTCTCTCTCTCT 65005

Qy 411 CTGTTCTTCAATTCATTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTGG 470
Db 65004 CTCCTTCAATTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTGG 470

Qy 471 GGGCTG 476
Db 64944 GCACTG 64939

RESULT 10

US-09-949-016-16275/c
; Sequence 16275, Application US/09949016
; Patent No. 6812339
; GENERAL INFORMATION:
; APPLICANT: VENTER, J. Craig et al.
; TITLE OF INVENTION: POLYMORPHISMS IN KNOWN GENES ASSOCIATED
; WITH HUMAN DISEASE, METHODS OF DETECTION AND USES THEREOF
; FILE REFERENCE: CL001307
; CURRENT APPLICATION NUMBER: US/09/949,016
; CURRENT FILING DATE: 2000-04-14
; PRIOR APPLICATION NUMBER: 60/241,755
; PRIOR FILING DATE: 2000-10-20
; PRIOR APPLICATION NUMBER: 60/237,768
; PRIOR FILING DATE: 2000-10-03
; PRIOR APPLICATION NUMBER: 60/231,498
; PRIOR FILING DATE: 2000-09-08
; NUMBER OF SEQ ID NOS: 207012
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 16275
; LENGTH: 79351
; TYPE: DNA
; ORGANISM: Human
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)...(79351)
; OTHER INFORMATION: n = A,T,C or G

US-09-949-016-16275

Query Match 5.7%; Score 36.4; DB 4; Length 79351;
Best Local Similarity 55.6%; Pred. No. 5.6;
Matches 70; Conservative 0; Mismatches 56; Indels 0; Gaps 0;

Qy 351 ATAGAGGCAAGATCTGAGTCCTTTTGAAGGCTATCCCTGCTGTATCTCAATTA 410
Db 65064 AAAGGAACAGAGATGTCAAGAGAGAGGATGTGTGTCTCTCTCTCTCTCT 65005

Qy 411 CTGTTCTTCAATTCATTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTGG 470
Db 65004 CTCCTTCAATTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTGG 470

Qy 471 GGGCTG 476
Db 64944 GCACTG 64939

RESULT 11

US-09-949-016-14193/c
; Sequence 14193, Application US/09949016
; Patent No. 6812339
; GENERAL INFORMATION:
; APPLICANT: VENTER, J. Craig et al.
; TITLE OF INVENTION: POLYMORPHISMS IN KNOWN GENES ASSOCIATED
; WITH HUMAN DISEASE, METHODS OF DETECTION AND USES THEREOF
; FILE REFERENCE: CL001307
; CURRENT APPLICATION NUMBER: US/09/949,016
; CURRENT FILING DATE: 2000-04-14
; PRIOR APPLICATION NUMBER: 60/241,755
; PRIOR FILING DATE: 2000-10-20
; PRIOR APPLICATION NUMBER: 60/237,768
; PRIOR FILING DATE: 2000-10-03
; PRIOR APPLICATION NUMBER: 60/231,498
; PRIOR FILING DATE: 2000-09-08
; NUMBER OF SEQ ID NOS: 207012
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 14193
; LENGTH: 247781
; TYPE: DNA
; ORGANISM: Human
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)...(247781)
; OTHER INFORMATION: n = A,T,C or G

US-09-949-016-14193

Query Match 5.7%; Score 36.4; DB 4; Length 247781;
Best Local Similarity 51.9%; Pred. No. 11;
Matches 82; Conservative 0; Mismatches 76; Indels 0; Gaps 0;

Qy 481 AGGCTGAGGAGATTGAGAGAGCAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 540
Db 126708 AGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 126649

Qy 541 GAGCTGAAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 600
Db 126648 GAAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 126589

Qy 601 GGGAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 638
Db 126588 GGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 126551

RESULT 12

US-09-949-016-13590
; Sequence 13590, Application US/09949016
; Patent No. 6812339
; GENERAL INFORMATION:
; APPLICANT: VENTER, J. Craig et al.
; TITLE OF INVENTION: POLYMORPHISMS IN KNOWN GENES ASSOCIATED
; WITH HUMAN DISEASE, METHODS OF DETECTION AND USES THEREOF

Query Match 5.5%; Score 35.4; DB 4; Length 120727;
Best Local Similarity 57.8%; Pred. No. 15;
Matches 63; Conservative 0; Mismatches 46; Indels 0; Gaps 0;

Qy 80 CATGTTTCCCTTAGCCACTCCCAGCTCGGTGAGGAAAGCGAGCCCTAACTAGGTACC 139
Db 17139 CAGCCTTTTGTCTCAGCTGCTCTCTGGTTCTGTGTCGAGAGGGAGGCCAGTGAGGATGC 17198

Qy 140 GTCTTCCCGACTTTGCTCAATGATAGCTGGGTGGGTCTAGCTGGGTTC 188
Db 17199 GTTTCGGGGAGTTTGCAGACTGCTAGGCGAGGCTGCCTAACCGAGTGCC 17247

Search completed: October 12, 2005, 09:35:50
Job time : 172 secs

THIS PAGE BLANK (05/10)

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: October 12, 2005, 09:32:55 ; Search time 2052 Seconds
(without alignments)
2168.876 Million cell updates/sec

Title: US-09-721-183-4
Perfect score: 639
Sequence: 1 ccgaacacgagtttagtcc.....cacgaatggacggaggagat 639

Scoring table: IDENTITY NUC
Gapop 10.0 , Gapext 1.0

Searched: 8443130 seqs, 3482420727 residues

Total number of hits satisfying chosen parameters: 16886260

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Published Applications NA:*

- 1: /cgn2_6/ptodata/1/pubpna/US07_PUBCOMB.seq.*
- 2: /cgn2_6/ptodata/1/pubpna/PCT_NEW_PUB.seq.*
- 3: /cgn2_6/ptodata/1/pubpna/US06_NEW_PUB.seq.*
- 4: /cgn2_6/ptodata/1/pubpna/US06_PUBCOMB.seq.*
- 5: /cgn2_6/ptodata/1/pubpna/US07_NEW_PUB.seq.*
- 6: /cgn2_6/ptodata/1/pubpna/PCTUS_PUBCOMB.seq.*
- 7: /cgn2_6/ptodata/1/pubpna/US08_NEW_PUB.seq.*
- 8: /cgn2_6/ptodata/1/pubpna/US08_PUBCOMB.seq.*
- 9: /cgn2_6/ptodata/1/pubpna/US09A_PUBCOMB.seq.*
- 10: /cgn2_6/ptodata/1/pubpna/US09B_PUBCOMB.seq.*
- 11: /cgn2_6/ptodata/1/pubpna/US09C_PUBCOMB.seq.*
- 12: /cgn2_6/ptodata/1/pubpna/US09_NEW_PUB.seq.*
- 13: /cgn2_6/ptodata/1/pubpna/US10A_PUBCOMB.seq.*
- 14: /cgn2_6/ptodata/1/pubpna/US10B_PUBCOMB.seq.*
- 15: /cgn2_6/ptodata/1/pubpna/US10C_PUBCOMB.seq.*
- 16: /cgn2_6/ptodata/1/pubpna/US10D_PUBCOMB.seq.*
- 17: /cgn2_6/ptodata/1/pubpna/US10E_PUBCOMB.seq.*
- 18: /cgn2_6/ptodata/1/pubpna/US10F_PUBCOMB.seq.*
- 19: /cgn2_6/ptodata/1/pubpna/US10G_PUBCOMB.seq.*
- 20: /cgn2_6/ptodata/1/pubpna/US10H_PUBCOMB.seq.*
- 21: /cgn2_6/ptodata/1/pubpna/US10I_PUBCOMB.seq.*
- 22: /cgn2_6/ptodata/1/pubpna/US10J_PUBCOMB.seq.*
- 23: /cgn2_6/ptodata/1/pubpna/US11A_PUBCOMB.seq.*
- 24: /cgn2_6/ptodata/1/pubpna/US11_NEW_PUB.seq.*
- 25: /cgn2_6/ptodata/1/pubpna/US60_NEW_PUB.seq.*
- 26: /cgn2_6/ptodata/1/pubpna/US60_PUBCOMB.seq.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	637.4	99.7	1104	16	US-10-082-828A-35
2	637.4	99.7	1104	24	US-11-057-807-35
3	306	47.9	307	16	US-10-082-828A-34
4	306	47.9	307	24	US-11-057-807-34
5	99.8	15.6	2112	17	US-10-104-047-1145
6	75.8	11.9	503	13	US-10-198-846-13943
7	45.2	7.1	202251	13	US-10-087-192-985

c	8	42	6.6	53522	10	US-09-904-968A-1	Sequence 1, Appli
c	9	39.2	6.1	540	19	US-10-021-323-1875	Sequence 1875, Ap
c	10	37.4	5.9	610	13	US-10-027-632-236295	Sequence 236295,
c	11	37.4	5.9	610	13	US-10-027-632-236296	Sequence 236296,
c	12	37.4	5.9	610	13	US-10-027-632-236297	Sequence 236297,
c	13	37.4	5.9	610	13	US-10-027-632-236298	Sequence 236298,
c	14	37.4	5.9	610	13	US-10-027-632-236299	Sequence 236299,
c	15	37.4	5.9	610	17	US-10-027-632-236295	Sequence 236295,
c	16	37.4	5.9	610	17	US-10-027-632-236296	Sequence 236296,
c	17	37.4	5.9	610	17	US-10-027-632-236297	Sequence 236297,
c	18	37.4	5.9	610	17	US-10-027-632-236298	Sequence 236298,
c	19	37.4	5.9	610	17	US-10-027-632-236299	Sequence 236299,
c	20	37.4	5.9	394468	21	US-10-741-600-17952	Sequence 17952, A
c	21	37.4	5.9	418550	17	US-10-292-798-1463	Sequence 1463, Ap
c	22	37.2	5.8	451	18	US-10-424-599-138280	Sequence 138280,
c	23	37.2	5.8	1038	13	US-10-036-729-3	Sequence 3, Appli
c	24	37.2	5.8	2839	18	US-10-425-114-32733	Sequence 32733, A
c	25	37.2	5.8	3134	20	US-10-425-115-119600	Sequence 119600,
c	26	36.6	5.7	195	19	US-10-437-963-20090	Sequence 20090, A
c	27	36.6	5.7	976	19	US-10-437-963-8451	Sequence 8451, Ap
c	28	36.2	5.7	11263	22	US-10-756-149-3787	Sequence 3787, Ap
c	29	36.2	5.7	203132	19	US-10-322-281-459	Sequence 459, App
c	30	36	5.6	1599	18	US-10-425-114-33012	Sequence 33012, A
c	31	36	5.6	1599	20	US-10-425-115-141198	Sequence 141198,
c	32	35.8	5.6	592	13	US-10-027-632-280778	Sequence 280778,
c	33	35.8	5.6	592	17	US-10-027-632-280778	Sequence 280778,
c	34	35.8	5.6	735	13	US-10-027-632-26656	Sequence 26656, A
c	35	35.8	5.6	735	17	US-10-027-632-26656	Sequence 26656, A
c	36	35.8	5.6	401433	22	US-10-737-082-79	Sequence 79, Appl
c	37	35.8	5.6	401433	22	US-10-765-790-79	Sequence 79, Appl
c	38	35.6	5.6	608	20	US-10-425-115-124398	Sequence 124398,
c	39	35.6	5.6	2230	17	US-10-108-260A-1530	Sequence 1530, Ap
c	40	35.6	5.6	7444	15	US-10-128-714-5176	Sequence 5176, Ap
c	41	35.6	5.6	7496	15	US-10-128-714-176	Sequence 176, App
c	42	35.6	5.6	25751	21	US-10-741-600-17722	Sequence 17722, A
c	43	35.6	5.6	38753	19	US-10-741-601-5767	Sequence 5767, Ap
c	44	35.4	5.5	222	18	US-10-424-599-130471	Sequence 130471, A
c	45	35.4	5.5	669	18	US-10-424-599-60426	Sequence 60426, A

ALIGNMENTS

RESULT 1
US-10-082-828A-35
; Sequence 35, Application US/10082828A
; Publication No. US20030175715A1
; GENERAL INFORMATION:
; APPLICANT: Sun, Yongming
; APPLICANT: Recipon, Herve
; APPLICANT: Salceda, Susana
; APPLICANT: Liu, Chenghua
; APPLICANT: Turner, Leah
; TITLE OF INVENTION: Compositions and Methods Relating to Breast Specific Genes and P
; FILE REFERENCE: DEX-0247
; CURRENT APPLICATION NUMBER: US/10/082,828A
; CURRENT FILING DATE: 2002-07-09
; PRIOR APPLICATION NUMBER: US 60/243,805
; PRIOR FILING DATE: 2000-10-27
; NUMBER OF SEQ ID NOS: 266
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 35
; LENGTH: 1104
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-082-828A-35

Query Match 99.7%; Score 637.4; DB 16; Length 1104;
Best Local Similarity 99.8%; Pred. No. 2.4e-194;
Matches 638; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1 CCGAACGAGTTAGTTCAGGTTCTCGTTCCGAATCTTCTCTTCTTCTTC 60
|||||

Db	466	CCAGAACGAGTTTAGTCCAGGTTCTCGTTCTGGCAAAATCTTCTCCTTACCTTCTTCC	525
Qy	61	TCCACCCCTCCACCTATGCCATGTTTTCCCTTACGCTCCCGAGCTCGGTGGAGGAAAG	120
Db	526	TCCACCCCTCCACCTATGCCATGTTTTCCCTTACGCTCCCGAGCTCGGTGGAGGAAAG	585
Qy	121	GCAGGCCCTAACTAGTAGTACCGTCTTCCGACATTTGCTCAATGATAGCTGGGTGGGTCTAGC	180
Db	586	GCAGGCCCTAACTAGTAGTACCGTCTTCCGACATTTGCTCAATGATAGCTGGGTGGGTCTAGC	645
Qy	181	TGGGTTCCAGCCACTTGAATGTGGGACATCTCTCACCCCAACTTTGTAGGTGAGCAAC	240
Db	646	TGGGTTCCAGCCACTTGAATGTGGGACATCTCTCACCCCAACTTTGTAGGTGAGCAAC	705
Qy	241	TGCTACAGAGGTAATATGATTAATCTTACATTCCTTCTGCTCGTCCCAACTTAA	300
Db	706	TGCTACAGAGGTAATATGATTAATCTTACATTCCTTCTGCTCGTCCCAACTTAA	765
Qy	301	CAGCAGGTAATCTGCTTTAGCAAGTGGTGAAGGTAAGAGAGCATCTGTATAGGAGGCA	360
Db	766	CAGCAGGTAATCTGCTTTAGCAAGTGGTGAAGGTAAGAGAGCATCTGTATAGGAGGCA	825
Qy	361	AGAGATCTGAGTCTTTTGAAGGCTATCTCTGCTCTGTATCTCAATTAATCTTCTTCA	420
Db	826	AGAGATCTGAGTCTTTTGAAGGCTATCTCTGCTCTGTATCTCAATTAATCTTCTTCA	885
Qy	421	TTTCAATTAATCTTACCTACTATTAGTTCCTTCTGATCTTTCTTCTTGGGGCTGTCTT	480
Db	886	TTTGAATTAATCTTACCTACTATTAGTTCCTTCTGATCTTTCTTCTTGGGGCTGTCTT	945
Qy	481	AGGTCAGGGAGATTGCAGAGCACCAAGACTAGGAGCAGCCCTGAGACATGGGGAGTTG	540
Db	946	AGGTCAGGGAGATTGCAGAGCACCAAGACTAGGAGCAGCCCTGAGACATGGGGAGTTG	1005
Qy	541	GAGCTGAAGGAGGAATGGCAGGATGAAGAAATCCCTAGGTGAGGACGTGTGAGGGTGGCT	600
Db	1006	GAGCTGAAGGAGGAATGGCAGGATGAAGAAATCCCTAGGTGAGGACGTGTGAGGGTGGCT	1065
Qy	601	GGGAGAGGGAGGGGTGGTACGAAATGGACGGAGGGAT	639
Db	1066	GGGAGAGGGAGGGGTGGTACGAAATGGACGGAGGGAT	1104
RESULT 2			
US-11-057-807-35			
; Sequence 35, Application US/11057807			
; Publication No. US20050136473A1			
; GENERAL INFORMATION:			
; APPLICANT: Sun, Yongming			
; APPLICANT: Recipon, Herve			
; APPLICANT: Salceda, Susana			
; APPLICANT: Liu, Chenghua			
; APPLICANT: Turner, Leah			
; TITLE OF INVENTION: Compositions and Methods Relating to Breast Specific Genes and Pr			
; FILE REFERENCE: DEX-0247			
; CURRENT APPLICATION NUMBER: US/11/057,807			
; PRIOR FILING DATE: 2005-02-14			
; PRIOR APPLICATION NUMBER: US/10/082,828			
; PRIOR FILING DATE: 2002-07-09			
; PRIOR APPLICATION NUMBER: US 60/243,805			
; PRIOR FILING DATE: 2000-10-27			
; NUMBER OF SEQ ID NOS: 266			
; SOFTWARE: PatentIn version 3.1			
; SEQ ID NO 35			
; LENGTH: 1104			
; TYPE: DNA			
; ORGANISM: Homo sapiens			
US-11-057-807-35			
Query Match 99.7%; Score 637.4; DB 24; Length 1104;			
Best Local Similarity 99.8%; Pred. No. 2.4e-194;			
Matches 638; Conservative 0; Mismatches 1; Indels 0; Gaps 0;			

Qy	1	CCAGAACCGAGTTTAGTCCAGGTTCTCGTTCTGGCAAAATCTTCTCCTTACCTTCTTCC	60
Db	466	CCAGAACCGAGTTTAGTCCAGGTTCTCGTTCTGGCAAAATCTTCTCCTTACCTTCTTCC	525
Qy	61	TCCACCCCTCCACCTATGCCATGTTTTCCCTTACGCTCCCGAGCTCGGTGGAGGAAAG	120
Db	526	TCCACCCCTCCACCTATGCCATGTTTTCCCTTACGCTCCCGAGCTCGGTGGAGGAAAG	585
Qy	121	GCAGGCCCTAACTAGTAGTACCGTCTTCCGACATTTGCTCAATGATAGCTGGGTGGGTCTAGC	180
Db	586	GCAGGCCCTAACTAGTAGTACCGTCTTCCGACATTTGCTCAATGATAGCTGGGTGGGTCTAGC	645
Qy	181	TGGGTTCCAGCCACTTGAATGTGGGACATCTCTCACCCCAACTTTGTAGGTGAGCAAC	240
Db	646	TGGGTTCCAGCCACTTGAATGTGGGACATCTCTCACCCCAACTTTGTAGGTGAGCAAC	705
Qy	241	TGCTACAGAGGTAATATGATTAATCTTACATTCCTTCTGCTCGTCCCAACTTAA	300
Db	706	TGCTACAGAGGTAATATGATTAATCTTACATTCCTTCTGCTCGTCCCAACTTAA	765
Qy	301	CAGCAGGTAATCTGCTTTAGCAAGTGGTGAAGGTAAGAGAGCATCTGTATAGGAGGCA	360
Db	766	CAGCAGGTAATCTGCTTTAGCAAGTGGTGAAGGTAAGAGAGCATCTGTATAGGAGGCA	825
Qy	361	AGAGATCTGAGTCTTTTGAAGGCTATCTCTGCTCTGTATCTCAATTAATCTTCTTCA	420
Db	826	AGAGATCTGAGTCTTTTGAAGGCTATCTCTGCTCTGTATCTCAATTAATCTTCTTCA	885
Qy	421	TTTCAATTAATCTTACCTACTATTAGTTCCTTCTGATCTTTCTTCTTGGGGCTGTCTT	480
Db	886	TTTGAATTAATCTTACCTACTATTAGTTCCTTCTGATCTTTCTTCTTGGGGCTGTCTT	945
Qy	481	AGGTCAGGGAGATTGCAGAGCACCAAGACTAGGAGCAGCCCTGAGACATGGGGAGTTG	540
Db	946	AGGTCAGGGAGATTGCAGAGCACCAAGACTAGGAGCAGCCCTGAGACATGGGGAGTTG	1005
Qy	541	GAGCTGAAGGAGGAATGGCAGGATGAAGAAATCCCTAGGTGAGGACGTGTGAGGGTGGCT	600
Db	1006	GAGCTGAAGGAGGAATGGCAGGATGAAGAAATCCCTAGGTGAGGACGTGTGAGGGTGGCT	1065
Qy	601	GGGAGAGGGAGGGGTGGTACGAAATGGACGGAGGGAT	639
Db	1066	GGGAGAGGGAGGGGTGGTACGAAATGGACGGAGGGAT	1104
RESULT 3			
US-10-082-828A-34			
; Sequence 34, Application US/10082828A			
; Publication No. US20030175715A1			
; GENERAL INFORMATION:			
; APPLICANT: Sun, Yongming			
; APPLICANT: Recipon, Herve			
; APPLICANT: Salceda, Susana			
; APPLICANT: Liu, Chenghua			
; APPLICANT: Turner, Leah			
; TITLE OF INVENTION: Compositions and Methods Relating to Breast Specific Genes and Pr			
; FILE REFERENCE: DEX-0247			
; CURRENT APPLICATION NUMBER: US/10/082,828			
; CURRENT FILING DATE: 2002-07-09			
; PRIOR APPLICATION NUMBER: US 60/243,805			
; PRIOR FILING DATE: 2000-10-27			
; NUMBER OF SEQ ID NOS: 266			
; SOFTWARE: PatentIn version 3.1			
; SEQ ID NO 34			
; LENGTH: 307			
; TYPE: DNA			
; ORGANISM: Homo sapiens			
; FEATURE:			
; NAME/KEY: misc feature			
; LOCATION: (28)-(28)			
; OTHER INFORMATION: n=a, c, g or t			
US-10-082-828A-34			

```
Query Match          47.9%; Score 306; DB 16; Length 307;
Best Local Similarity 99.7%; Pred. No. 9.3e-88;
Matches 306; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 333 GGTAAAGAAGCATCTGTATAGGAGGCAAGAGATCTGAGTCTCTTTTGAAGGCTATCTCTC 392
Db 1 GGTAAAGAAGCATCTGTATAGGAGGCAAGAGATCTGAGTCTCTTTTGAAGGCTATCTCTC 60

Qy 393 TGCTCTGTATCTCAATTAATCTGTTCTTCAATTTCAATTAATCTTACCTACTATTCAGTTCCC 452
Db 61 TGCTCTGTATCTCAATTAATCTGTTCTTCAATTTCAATTAATCTTACCTACTATTCAGTTCCC 120

Qy 453 TTGATCTTTTCTCTTGGGGCTGCTTAGGCTCAGGGAGATTCGAGAAGCACCAGAACT 512
Db 121 TTGATCTTTTCTCTTGGGGCTGCTTAGGCTCAGGGAGATTCGAGAAGCACCAGAACT 180

Qy 513 AGGAGCAGCCCTGAGACATGGGGAGTGGAGCTGAAGCAGGAATGGCAGGATGAAGAATT 572
Db 181 AGGAGCAGCCCTGAGACATGGGGAGTGGAGCTGAAGCAGGAATGGCAGGATGAAGAATT 240

Qy 573 CCCTAGGTGAGACCTGTGAGGGTGGCTGGGAGAAAGGAGGGTGGTCAAGAAATGGACGG 632
Db 241 CCCTAGGTGAGACCTGTGAGGGTGGCTGGGAGAAAGGAGGGTGGTCAAGAAATGGACGG 300

Qy 633 AGGGGAT 639
Db 301 AGGGGAT 307

RESULT 4
US-11-057-807-34
; Sequence 34, Application US/11057807
; Publication No. US20050136473A1
; GENERAL INFORMATION:
; APPLICANT: Sun, Yongming
; APPLICANT: Recipon, Herve
; APPLICANT: Salceda, Susana
; APPLICANT: Liu, Chenghua
; APPLICANT: Turner, Leah
; TITLE OF INVENTION: Compositions and Methods Relating to Breast Specific Genes and P
; FILE REFERENCE: DEX-0247
; CURRENT APPLICATION NUMBER: US/11/057,807
; CURRENT FILING DATE: 2005-02-14
; PRIOR APPLICATION NUMBER: US/10/082,828
; PRIOR FILING DATE: 2002-07-09
; PRIOR APPLICATION NUMBER: US 60/243,805
; PRIOR FILING DATE: 2000-10-27
; NUMBER OF SEQ ID NOS: 266
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 34
; LENGTH: 307
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (28)..(28)
; OTHER INFORMATION: n=a, c, g or t
US-11-057-807-34

Query Match          47.9%; Score 306; DB 24; Length 307;
Best Local Similarity 99.7%; Pred. No. 9.3e-88;
Matches 306; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 333 GGTAAAGAAGCATCTGTATAGGAGGCAAGAGATCTGAGTCTCTTTTGAAGGCTATCTCTC 392
Db 1 GGTAAAGAAGCATCTGTATAGGAGGCAAGAGATCTGAGTCTCTTTTGAAGGCTATCTCTC 60

Qy 393 TGCTCTGTATCTCAATTAATCTGTTCTTCAATTTCAATTAATCTTACCTACTATTCAGTTCCC 452
Db 61 TGCTCTGTATCTCAATTAATCTGTTCTTCAATTTCAATTAATCTTACCTACTATTCAGTTCCC 120

Qy 453 TTGATCTTTTCTCTTGGGGCTGCTTAGGCTCAGGGAGATTCGAGAAGCACCAGAACT 512
```

```
Db 121 TTGATCTTTTCTCTTGGGGCTGCTTAGGCTCAGGGAGATTCGAGAAGCACCAGAACT 180

Qy 513 AGGAGCAGCCCTGAGACATGGGGAGTGGAGCTGAAGCAGGAATGGCAGGATGAAGAATT 572
Db 181 AGGAGCAGCCCTGAGACATGGGGAGTGGAGCTGAAGCAGGAATGGCAGGATGAAGAATT 240

Qy 573 CCCTAGGTGAGACCTGTGAGGGTGGCTGGGAGAAAGGAGGGTGGTCAAGAAATGGACGG 632
Db 241 CCCTAGGTGAGACCTGTGAGGGTGGCTGGGAGAAAGGAGGGTGGTCAAGAAATGGACGG 300

Qy 633 AGGGGAT 639
Db 301 AGGGGAT 307

RESULT 5
US-10-104-047-1145
; Sequence 1145, Application US/10104047
; Publication No. US20030236392A1
; GENERAL INFORMATION:
; APPLICANT: HELIX RESEARCH INSTITUTE
; TITLE OF INVENTION: NO. US20030236392A1el full length cDNA
; FILE REFERENCE: H1-A0105
; CURRENT APPLICATION NUMBER: US/10/104,047
; CURRENT FILING DATE: 2002-03-25
; PRIOR APPLICATION NUMBER:
; PRIOR FILING DATE:
; NUMBER OF SEQ ID NOS: 4096
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 1145
; LENGTH: 2112
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-104-047-1145

Query Match          15.6%; Score 99.8; DB 17; Length 2112;
Best Local Similarity 89.9%; Pred. No. 8e-21;
Matches 107; Conservative 0; Mismatches 12; Indels 0; Gaps 0;

Qy 477 TCTTAGGTCTAGGAGATTTGAGAGCAGCAGAACTAGGAGCAGCCCTGAGACATGGGGA 536
Db 161 TGTGGGGTCTAGGAGATTTGAGAGCAGCAGAACTAGGAGCAGCCCTGAGACATGGGGA 220

Qy 537 GTTGAGCTGAAGAGGAGTGGCAGGATGAAGAAATTCCTAGTGAGGACGTGTGAGG 595
Db 221 GTTGAGCTGAAGAGGAGTGGCAGGATGAAGAAATTCCTAGTGAGGAGG 279

RESULT 6
US-10-198-846-13943/c
; Sequence 13943, Application US/10198846
; Publication No. US2003009974A1
; GENERAL INFORMATION:
; APPLICANT: Lillie, James
; APPLICANT: Xu, Yongyao
; APPLICANT: Wang, Youzhen
; APPLICANT: Steinmann, Kathleen
; TITLE OF INVENTION: NOVEL GENES, COMPOSITIONS, KITS, AND METHODS
; TITLE OF INVENTION: FOR IDENTIFICATION, ASSESSMENT, PREVENTION, AND
; TITLE OF INVENTION: THERAPY OF BREAST CANCER
; FILE REFERENCE: MRI-049
; CURRENT APPLICATION NUMBER: US/10/198,846
; CURRENT FILING DATE: 2002-07-18
; PRIOR APPLICATION NUMBER: 60/306,220
; PRIOR FILING DATE: 2001-07-18
; NUMBER OF SEQ ID NOS: 14084
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 13943
; LENGTH: 503
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: misc_feature
```



```
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 236297
; LENGTH: 610
; TYPE: DNA
; ORGANISM: Human
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (1)..(610)
; OTHER INFORMATION: n = A,T,C or G
US-10-027-632-236297

Query Match          5.9%; Score 37.4; DB 13; Length 610;
Best Local Similarity 52.2%; Pred. No. 0.56;
Matches 83; Conservative 0; Mismatches 76; Indels 0; Gaps 0;

Qy 309 AATCGCTTCTAGCAAGTGGTGAAGGTAAGAGGATCTGTATAGAGGCAAGAGATCT 368
Db 565 AGTTTCCCTTTAGCCAAAGGAAGAGGAAAAAATGAATGCATAGAGATCCATGTAGATCA 506
;
Qy 369 GAGTCCTTTTGAAGGCCATCTCTGCTCTGTATCTCAATTACTGTCTTCTTCAATT 428
Db 505 GTGGCTCTTGAATCTTTATCTTAACTTCCCAACTCTATATTAT 407
;
Qy 429 ATTCTTACCTACTATTCCAGTTCCCTTGATCTTTTCTTCT 467
Db 445 AGTTTGGCATTTCTTAAATTTTCCCAACTCTATATTAT 407
;

RESULT 14
US-10-027-632-236299/c
; Sequence 236299, Application US/10027632
; Publication No. US20020198371A1
; GENERAL INFORMATION:
; APPLICANT: Wang, David G.
; TITLE OF INVENTION: Identification and Mapping of Single Nucleotide
; FILE OF INVENTION: Polymorphisms in the Human Genome
; FILE REFERENCE: 108827.129
; CURRENT APPLICATION NUMBER: US/10/027,632
; CURRENT FILING DATE: 2002-04-30
; PRIOR APPLICATION NUMBER: US 60/218,006
; PRIOR FILING DATE: 2000-07-12
; PRIOR APPLICATION NUMBER: US 60/198,676
; PRIOR FILING DATE: 2000-04-20
; PRIOR APPLICATION NUMBER: US 60/193,483
; PRIOR FILING DATE: 2000-03-29
; PRIOR APPLICATION NUMBER: US 60/185,218
; PRIOR FILING DATE: 2000-02-24
; PRIOR APPLICATION NUMBER: US 60/167,363
; PRIOR FILING DATE: 1999-11-23
; PRIOR APPLICATION NUMBER: US 60/156,358
; PRIOR FILING DATE: 1999-09-28
; PRIOR APPLICATION NUMBER: US 60/146,002
; PRIOR FILING DATE: 1999-08-09
; NUMBER OF SEQ ID NOS: 325720
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 236299
; LENGTH: 610
; TYPE: DNA
; ORGANISM: Human
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (1)..(610)
; OTHER INFORMATION: n = A,T,C or G
US-10-027-632-236299

Query Match          5.9%; Score 37.4; DB 13; Length 610;
Best Local Similarity 52.2%; Pred. No. 0.56;
Matches 83; Conservative 0; Mismatches 76; Indels 0; Gaps 0;

Qy 309 AATCGCTTCTAGCAAGTGGTGAAGGTAAGAGGATCTGTATAGAGGCAAGAGATCT 368
Db 565 AGTTTCCCTTTAGCCAAAGGAAGAGGAAAAAATGAATGCATAGAGATCCATGTAGATCA 506
;
Qy 369 GAGTCCTTTTGAAGGCCATCTCTGCTCTGTATCTCAATTACTGTCTTCTTCAATT 428
Db 505 GTGGCTCTTGAATCTTTATCTTAACTTCCCAACTCTATATTAT 407
;
Qy 429 ATTCTTACCTACTATTCCAGTTCCCTTGATCTTTTCTTCT 467
Db 445 AGTTTGGCATTTCTTAAATTTTCCCAACTCTATATTAT 407
;

RESULT 13
US-10-027-632-236298/c
; Sequence 236298, Application US/10027632
; Publication No. US20020198371A1
; GENERAL INFORMATION:
; APPLICANT: Wang, David G.
; TITLE OF INVENTION: Identification and Mapping of Single Nucleotide
; FILE OF INVENTION: Polymorphisms in the Human Genome
; FILE REFERENCE: 108827.129
; CURRENT APPLICATION NUMBER: US/10/027,632
; CURRENT FILING DATE: 2002-04-30
; PRIOR APPLICATION NUMBER: US 60/218,006
; PRIOR FILING DATE: 2000-07-12
; PRIOR APPLICATION NUMBER: US 60/198,676
; PRIOR FILING DATE: 2000-04-20
; PRIOR APPLICATION NUMBER: US 60/193,483
; PRIOR FILING DATE: 2000-03-29
; PRIOR APPLICATION NUMBER: US 60/185,218
; PRIOR FILING DATE: 2000-02-24
; PRIOR APPLICATION NUMBER: US 60/167,363
; PRIOR FILING DATE: 1999-11-23
; PRIOR APPLICATION NUMBER: US 60/156,358
; PRIOR FILING DATE: 1999-09-28
; PRIOR APPLICATION NUMBER: US 60/146,002
; PRIOR FILING DATE: 1999-08-09
; NUMBER OF SEQ ID NOS: 325720
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 236298
; LENGTH: 610
; TYPE: DNA
; ORGANISM: Human
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (1)..(610)
; OTHER INFORMATION: n = A,T,C or G
US-10-027-632-236298

Query Match          5.9%; Score 37.4; DB 13; Length 610;
Best Local Similarity 52.2%; Pred. No. 0.56;
Matches 83; Conservative 0; Mismatches 76; Indels 0; Gaps 0;

Qy 309 AATCGCTTCTAGCAAGTGGTGAAGGTAAGAGGATCTGTATAGAGGCAAGAGATCT 368
Db 565 AGTTTCCCTTTAGCCAAAGGAAGAGGAAAAAATGAATGCATAGAGATCCATGTAGATCA 506
;

RESULT 15
US-10-027-632-236295/c
; Sequence 236295, Application US/10027632
; Publication No. US20030204075A9
; GENERAL INFORMATION:
; APPLICANT: Wang, David G.
; TITLE OF INVENTION: Identification and Mapping of Single Nucleotide
; FILE OF INVENTION: Polymorphisms in the Human Genome
; FILE REFERENCE: 108827.129
; CURRENT APPLICATION NUMBER: US/10/027,632
```

```
; CURRENT FILING DATE: 2002-04-30
; PRIOR APPLICATION NUMBER: US 60/218,006
; PRIOR FILING DATE: 2000-07-12
; PRIOR APPLICATION NUMBER: US 60/198,676
; PRIOR FILING DATE: 2000-04-20
; PRIOR APPLICATION NUMBER: US 60/193,483
; PRIOR FILING DATE: 2000-03-29
; PRIOR APPLICATION NUMBER: US 60/185,218
; PRIOR FILING DATE: 2000-02-24
; PRIOR APPLICATION NUMBER: US 60/167,363
; PRIOR FILING DATE: 1999-11-23
; PRIOR APPLICATION NUMBER: US 60/156,358
; PRIOR FILING DATE: 1999-09-28
; PRIOR APPLICATION NUMBER: US 60/146,002
; PRIOR FILING DATE: 1999-08-09
; NUMBER OF SEQ ID NOS: 325720
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 236295
; LENGTH: 610
; TYPE: DNA
; ORGANISM: Human
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (1)..(610)
; OTHER INFORMATION: n = A,T,C or G
US-10-027-632-236295
```

```
Query Match      5.9%; Score 37.4; DB 17; Length 610;
Best Local Similarity 52.2%; Pred. No. 0.56;
Matches 83; Conservative 0; Mismatches 76; Indels 0; Gaps 0;

Qy 309 AATCTGCTTCTAGCAAGTGGTAAGAGAGCAATCTGTATAGGAGGCAAGAGATCT 368
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 565 AGTTTCCCTTTAGCCAGGAAGAGAAAAAATGAATGCATAGAGATCCCATGTAGATCA 506
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

Qy 369 GAGTCCTTTTGAAGCCCTATCCTCTGCTCTGATCTCAATTACTGTTCTTCAATT 428
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 505 GTGGCTCTTGAATTCCTTTATCCTAAGATCTGTTTCTCTCATTCATTCCTATCCAC 446
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

Qy 429 ATTCTTACTACTATATCAGTTCCCTTGATCTTTTCTTCT 467
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 445 AGTTTGGCATCTTAAATTTTCCCAACTCCTATATTTAT 407
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
```

Search completed: October 12, 2005, 10:18:19
Job time : 2054 secs

THIS PAGE BLANK (USPTO)